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ABSTRACT 
To predict the toxicity of nanoparticles (1-100 nm), it is crucial to understand their 
biokinetics i.e. how they are taken up, distributed, dissolved and removed from the body. 
Such information can be gained from biodistribution studies in animals. However, to make 
predictions for other types of nanoparticles, exposure conditions and species, including 
humans, extrapolations from such studies are required. Use of models, such as 
physiologically based pharmacokinetic (PBPK) models, makes extrapolations feasible, given 
that the models are sufficiently validated.  
In this thesis, a conceptual nanospecific PBPK model for intravenous administration to rats 
was developed and applied to different types of inert nanoparticles using experimental data 
from recent scientific publications (Papers I and II). The model represents systemic 
distribution and serves as a foundation for expansion to other species and other exposure 
routes (inhalation, dermal, oral). The PBPK simulations suggest that the model is able to 
describe the biokinetics of different types of inert nanoparticles given intravenously despite 
large differences in properties and exposure conditions. Our model is the first to include 
separate compartments for phagocytic cells and saturable phagocytosis. The simulations 
show that (1) phagocytosis needs to be incorporated in nano PBPK models, (2) the dose has a 
clear impact on biokinetics, but (3) further refinements are needed to better reflect processes 
such as agglomeration, corona formation and dissolution. The model was slightly modified to 
describe the biodistribution and biokinetics of nanoceria of different sizes and administered 
via other routes (Paper III). While the model could well predict the biokinetics after 
intravenous dosing, the predictions of inhalation, instillation and ingestion data were poor. 
The poor agreement may be partly due to low absorption via these routes, resulting in low 
nanoceria levels in tissues and organs, often close to or below the detection limit, in tissues. 
However, low absorption is hardly the only explanation, as the experimentally observed 
concentration time courses of nanoceria in tissues suggest that the biokinetics depend not 
only on the nanoparticle properties (size, coating) but also on the exposure conditions (dose, 
exposure route). The PBPK model was further developed to account for the complexity of 
inhalation exposure to nanoparticles (Paper IV). The modified model includes regional 
particle deposition in the respiratory tract, mucociliary clearance and phagocytosis in the 
lungs, olfactory uptake, and transport into the systemic circulation by alveolar wall 
translocation. The PBPK model described the biodistribution well and again suggested 
phagocytosis to be very important. 
The PBPK simulations were performed assuming that the nanoparticles are inert, i.e. do not 
dissolve or degrade in the body. However, when modelling the experimental data it seemed 
that the biokinetics might be better explained by introducing dissolution in the PBPK model. 
A related problem is that most experimental studies of metal nanoparticles use elemental 
analysis such as inductively coupled plasma mass spectrometry (ICP-MS). Such analyses do 
not discriminate between different forms of metal and therefore obscures the biokinetics. To 
test if gold nanoparticles dissolve in biological media, we developed an in vitro method to 
characterize dissolution of gold nanoparticles in contact with cell medium, macrophages and 
lipopolysaccharide (LPS)-triggered macrophages, simulating a disease state (Paper V). We 
demonstrated that gold nanoparticles are dissolved by cell medium and macrophages and 
even more so by LPS-triggered macrophages. The dissolution rate was higher for 5 nm than 
for 50 nm gold particles.  
SVENSK SAMMANFATTNING 
För att kunna förstå och förutse om nanopartiklar (1-100 nm) kan skada människor, är det 
viktigt att ha kunskap om nanopartiklars biokinetik d.v.s. hur de tas upp, distribueras, bryts 
ner i och utsöndras ur kroppen. Denna typ av information kan vi få från biodistributions-
studier på djur. För att göra prognoser för andra typer av nanopartiklar, exponeringsför-
hållanden och arter, inklusive människor, behöver vi oftast göra extrapoleringar utifrån den 
information vi har. Användning av tillräckligt validerade modeller, såsom fysiologiskt 
baserade farmakokinetiska (PBPK) modeller möjliggör sådana extrapoleringar. 
I denna avhandling har en konceptuell PBPK modell för intravenöst administrerade nano-
partiklar i råttor utvecklats och tillämpats på olika typer av stabila partiklar med hjälp av 
experimentella data hämtade från vetenskapliga publikationer (Studie I och II). Modellen 
representerar systemisk distribution och fungerar som bas för expansion till andra arter och 
andra exponeringsvägar (inandning, oralt, via huden). PBPK simuleringar visar att modellen 
kan beskriva biokinetiken för olika typer av stabila nanopartiklar som administreras intra-
venöst, trots stora skillnader i egenskaper och exponeringsförhållanden. Vår modell är den 
första att inkludera modellstrukturer för fagocyterande celler och deras upptagsprocesser. 
Simuleringarna visar att (1) fagocytos borde inkluderas i PBPK modeller för nanopartiklar, 
(2) dosen har en tydlig påverkan på biokinetik, men (3) ytterligare förbättringar behövs för att 
bättre återspegla processer såsom agglomerering, koronabildning och nedbrytning. Modellen 
ändrades något för att kunna beskriva biodistribution och biokinetik av nanoceria med olika 
storlekar och administrerade via olika exponeringsvägar (Studie III). Medan modellen väl 
förutsåg biokinetik för intravenös dosering så beskrev modellen kinetiken dåligt för 
inandning, instillation och förtäring. Den dåliga modellanpassningen kan delvis bero på låg 
absorption via dessa exponeringsvägar, vilket leder till låga nivåer av nanoceria i organ, ofta 
nära eller under detektionsgränsen. Låg absorption är troligen inte den enda förklaringen, 
eftersom tidsförloppen i experimentella data tyder på att biokinetik utöver nanopartiklars 
egenskaper (storlek, beläggning) också påverkas av exponeringsförhållandena (dos, 
exponeringsväg). PBPK modellen vidareutvecklades för att bättre beskriva den komplexa 
inhalationsexponeringen. Modellen inkluderar regional deponering av partiklar i luftvägarna, 
mukociliär transport och upptag i alveolära makrofager, transport via luktnerv till hjärna och 
upptag från lunga till blod (Studie IV). Modellen beskrev biokinetiken för nanoceria väl och 
visade igen på vikten av fagocytos som en del i PBPK modeller för nanopartiklar. 
Våra PBPK simuleringar utfördes med antagande om att partiklarna var stabila, d.v.s. de bröts 
inte ner i kroppen. När vi utförde modellsimulering på experimentella data för bl.a. 
nanopartiklar av guld så verkade det som om biokinetiken troligen bättre skulle kunna 
förklaras om nedbrtyning inkluderades i modellen. Ett relaterat problem är att de flesta 
experimentella biodistributionsstudier med nanopartiklar i metall använder elementaranalys, 
såsom induktivt kopplad plasma-masspektrometri (ICP-MS), för att analysera mängd metall i 
organ. Denna typ av analys kan inte särskilja olika former av metall och därmed inte heller 
skillnader i biokinetik mellan dessa. För att testa om nanopartiklar av guld bryts ner i 
biologisk miljö, utvecklade vi en in vitro-metod för att undersöka om nanopartiklar i guld 
bryts ner i kontakt med cellmedium, makrofager och lipopolysackarid (LPS) -stressade 
makrofager (Studie V). Vi visade att guldpartiklarna bryts ner av cellmedium och av 
makrofager, och ännu mer om makrofagerna stressades med LPS. Nedbrytningen var 
snabbare för 5 nm än för 50 nm stora guldpartiklar. 
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1 INTRODUCTION 
Nanotechnology is an innovative and evolving field where new products are continuously 
introduced on the market. In the healthcare and medicine sector alone, the global market is 
estimated to increase from $30 billion in 2014 to $80 billion in 2019 (James et al., 2014). The 
benefits with nanotechnology are numerous and provide hope for solving many global 
problems such as diseases, global warming, and shortage of water and food.  
Particles of a nanometre scale, often called nanoparticles, have unique properties, including 
superparamagnetism, catalytic activity and durability, as well as unexpected optical 
characteristics and increasing the strength of materials. For these reasons, nanoparticles have 
become popular components of products and contribute to the improvement in many sectors, 
such as information technology, energy, transportation, construction, environmental science, 
medicine, and food (Lee et al., 2010; Duncan, 2011; Parveen et al., 2012; Raj et al., 2012; 
Wang et al., 2012; Waser, 2012; Qu et al., 2013).  
To ensure a continuous and sustainable development, nanoparticles must be safe for humans 
and the environment. Meanwhile, the increasing use of nanoparticles increases the likelihood 
of exposure and thereby the risk for unintended consequences to human health and the 
environment. In addition to intentional exposure, e.g. when used in pharamceutical 
applications, and unintentional expsoure during manufacturing, use and disposal, 
nanoparticles may be released from products, resulting in secondary human exposure via the 
skin, lungs, eyes and or mouth (Buzea et al., 2007; Nowack et al., 2013; Liou et al., 2015). 
Great efforts have been made to evaluate the health effects of nanomaterials on humans, but 
the results are inconclusive so far (Sharifi et al., 2012; Liou et al., 2015; Zhang et al., 2015). 
Most studies have been carried out in vitro and with animals. Data from exposed humans are 
rare although the number of epidemiological studies is increasing (Liou et al., 2015). 
Because of their extremely small size, similar to that of the structural elements of cells, there 
is concern that nanoparticles may be toxic, as has indeed been reported in both in vitro and in 
vivo studies (Buzea et al., 2007; Krug et al., 2011; Kermanizadeh et al., 2015). To exert 
toxicity, these particles must reach the cell, i.e., become bioavailable in sufficiently high 
amounts. Several methods provide valuable information concerning the absorption, 
distribution, metabolism (degradation/dissolution) and excretion of nanoparticles. In vitro 
studies give insight into the mechanisms of action of various cellular processes; whereas in 
vivo studies can be employed to characterize the biodistribution in living animals (Marquis et 
al., 2009). Furthermore, in silico tools such as physiologically based pharmacokinetic 
(PBPK) models can be used to combine in vitro and in vivo data with an aim of predicting the 
final outcome in terms of the relation between exposure/dose and health effects (Krishnan et 
al., 2010; Johanson, 2014). 
The advantage of PBPK modelling is that toxicological data can be extrapolated from 
animals to humans, from high to low doses and between different routes of exposure, without 
additional in vitro and/or in vivo investigations (IPCS, 2010; Krishnan et al., 2010; Johanson, 
2014). However, only a few PBPK models have been published for nanoparticles to date and 
these are difficult to apply to other types of nanoparticles and exposure conditions because 
their physiological basis is limited (Li et al., 2010; Bachler et al., 2013; Kolanjiyil et al., 
2013; Lin et al., 2015b; Johanson et al., 2016). More physiologically relevant models are 
required for trustworth extrapolations. 
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2 BACKGROUND 
2.1 NANOPARTICLES 
Nanoparticles are small, with sizes similar to the structural elements of cells, antibodies, 
proteins and viruses. A common definition is any shape with dimensions between 1 to 100 
nm, but this may vary depending on regulatory framework (ISO, 2008; European 
Commission, 2011; FDA, 2014). They occur naturally, but are also produced by humans, on 
purpose or inadvertently (Buzea et al., 2007).   
Nanoparticles can be distributed in gaseous form, as liquids or deposited on solid materials 
and their properties can be tailored to have extraordinary characteristics, different from 
molecules and bulk materials (Roduner, 2006). One such characteristic is enhanced quantum 
and plasmon effects, giving nanoparticles intense colours useful for biological imaging and 
sensing (Michalet et al., 2005; Scholl et al., 2012). Another property is superparamagnetism, 
which makes nanoparticles susceptible to magnetic fields and hence valuable for MRI 
imaging, data storage and wastewater treatment etc.(Frey et al., 2009; Reddy et al., 2012; Xu 
et al., 2012; Qu et al., 2013). A third property is chemical activity, and this, together with 
increased surface area to volume ratio, makes nanoparticles excellent catalysts (Guo et al., 
2013; Liu et al., 2014). Typically, properties are tuned by changing particle size, geometry, 
and chemistry. Therefore, information about the nanoparticles’ physicochemical properties is 
crucial in nanoparticle design, applications, and risk assessment. 
However, physicochemical characterization of nanoparticles is challenging and may change 
with environment and exposure conditions (Oberdorster et al., 2005a; Fadeel et al., 2015). To 
open for proper interpretation of results from toxicity and biodistribution studies, the 
Organization for Economic Co-operation and Development (OECD) recommends that 
nanoparticles are characterized at least as received from the suppliers, administrated and in 
situ (OECD, 2012). However, this is rarely carried out in research studies. Properties of 
importance to characterize are: size, size distribution, surface area, shape, crystal structure, 
chemical composition, surface charge, surface energy, surface coatings, solubility, 
agglomeration state and impurities. All these parameters have been reported to modify 
toxicity and biodistribution (Oberdorster et al., 2005a; Aillon et al., 2009; Nel et al., 2009; 
Hussain et al., 2015). In this thesis, the focus is on engineered nanoparticles that are 
considered inert.  
 Toxicity  2.1.1
The toxicity of nanoparticles depends on their physicochemical characteristics and how they 
interact with cellular and molecular substances in the body (Aillon et al., 2009; Nel et al., 
2009; Zhu et al., 2010). Nanoparticles can absorb and release substances, and can join 
together to form agglomerates (loosely attached group of particles) or aggregates (tightly 
attached group of particles) (Jiang et al., 2009; Gliga et al., 2014). Moreover, they can 
catalyse or participate in chemical and biological reactions (Daniel et al., 2004). As a result of 
this dynamic interaction, the particle identity and its hazard potential may change with time 
and environment.  
Through their surfaces, nanoparticles interact with the surrounding environment and their 
surfaces are potentially more reactive compared with larger particles because of increased 
surface area to volume ratio. Actually, surface area has been proposed to be a better dose 
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metric for toxicity than mass or number of nanoparticles (Oberdorster et al., 2005b; 
Braakhuis et al., 2016; Schmid et al., 2016). Despite this, mass is probably the most 
commonly used dose metric in toxicity studies and volume has been used to describe the 
overload phenomenon caused by inhaled nanoparticles (Morrow, 1988; Pauluhn, 2014; 
Kermanizadeh et al., 2015).  
As a consequence of the wide range of nanoparticle properties, toxicity and mechanisms of 
toxicity differ considerably. In vitro studies show that nanoparticles can trigger a variety of 
toxicological mechanisms, such as release of reactive oxygen species (ROS), DNA damage, 
inflammatory effects and cell death through various mechanisms including autophagy (Stern 
et al., 2012; Gliga et al., 2014; Magdolenova et al., 2014). Sometimes the toxicity is not 
related to the nanoparticles themselves, but rather to the release of other substances, as 
observed for some metallic nanoparticles through a process called ―The Trojan horse effect‖, 
i.e. when cells take up nanoparticles, which release metallic ions inside the cells and cause 
toxicity (Limbach et al., 2007).  Another effect is the presence in nanoparticles of endotoxins 
that can induce inflammation (Vallhov et al., 2006). Excessively high concentrations are 
often used in vitro and hence do not always reflect environmental exposures accurately (Krug 
et al., 2011).  
In vivo, toxicity has been investigated after exposure to nanoparticles via inhalation, 
instillation, and dermal, oral, intraperitoneal and intravenous routes (Kermanizadeh et al., 
2015). The majority of the studies focus on animals and short-term exposure. Only a few 
studies included repeated and long-term exposure and long post-exposure follow-up times. 
The number of epidemiological studies is small, but growing (Liou et al., 2015). Studies 
indicate health effects related to exposure to nanomaterials, such as increased expression of 
cardiovascular and oxidative biomarkers, reduced levels of antioxidant enzymes, allergic 
dermatitis and increased sneezing as an indicator of airway irritation. However, most of these 
studies are cross-sectional and cover small numbers of participants, low exposures and short 
intervals between exposure and effect. In addition, exposure assessments are inconsistent and 
only a few types of nanoparticles have been covered. On the other hand, nanotoxicology is 
linked to particle and fibre toxicology and lessons learned from this field on ultrafine particles 
are relevant for nanoparticles as well, such as deposition pattern, particle overload in the lung, 
and particle toxicity as oxidative stress, cardiovascular diseases and the fibre paradigm 
(Oberdorster et al., 2005b; Donaldson et al., 2012; Grosse et al., 2014; Borm et al., 2015).  
Despite low uptake in the body via inhalation, skin contact and ingestion, adverse effects in a 
variety of distal organs have been reported (Kermanizadeh et al., 2015). Locally the 
deposition of nanoparticles may be higher and contributes to the toxicity (Balashazy et al., 
2003). In human and animal inhalation studies, nanoparticles have induced inflammation, 
pulmonary fibrosis, granuloma formation, cardiovascular effects and lung tumours (Brook, 
2008; Kermanizadeh et al., 2015). Oral studies in rats with nanoceria demonstrate effects on 
distal organs such as liver, brain and kidney (Kumari et al., 2014a; Kermanizadeh et al., 
2015). Results from repeated dermal exposure in guinea pigs of silver nanoparticles suggest 
cardiotoxicity, nephrotoxicity and osteotoxicity (Korani et al., 2011; Kermanizadeh et al., 
2015). Much like in studies in vitro, the doses used are often far higher than expected human 
exposure. Dissolved and released entities can also contribute to the observed toxicity (Park et 
al., 2010; Gliga et al., 2014). In short and as expected, toxicity differs widely depending on 
nanoparticle properties and exposure conditions. Several on-going efforts are made to group 
nanomaterials for testing, read-across, risk assessments and safety-by-design (Arts et al., 
2015; Geraci et al., 2015; EU NanoSafety Cluster, 2016; OECD, 2016). 
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Oxidative stress is commonly induced by nanoparticles through many different mechanisms 
as a result of the particles’ intrinsic properties or by interaction with cells (Nel et al., 2006; 
Xia et al., 2006; Manke et al., 2013). Surface reactivity is an intrinsic property and may be 
involved in the production of reactive oxygen species via oxidation and Fenton-like 
processes. When nanoparticles interact with cells like macrophages and neutrophils, the cells 
may respond by release of oxygen species in an attempt to remove the particles and/or signal 
stress. Reactive oxygen species are, on the other hand, produced endogenously during vital 
processes like cell breathing and oxidative burst, in which superoxide (O2
-
, HO2
•
), hydrogen 
peroxide (H2O2) and hydroxyl radicals (
•
OH) are formed (Halliwell et al., 2015). To 
neutralize the reactive oxygen species and protect itself from injuries, the cell uses 
antioxidant enzymes and proteins, such as glutathione, vitamins C and D, superoxide 
dismutase, and peroxidase. If the production of reactive oxygen species gets too high the 
redox homeostasis is disturbed, which may result in membrane lipid peroxidation, stress 
signalling, cell pathogenesis, and, ultimately, cell death. Uncontrolled oxidative stress can 
result in inflammation and progress into cardiovascular diseases, pulmonary fibrosis and 
tumour formation. 
 In vivo biodistribution  2.1.2
The target dose determines the toxicity. Correlating exposure to target dose information about 
biokinetics is essential. Biokinetics describes how nanoparticles are taken up, transported, 
dissolved and removed from the body over time and are based on biodistribution studies. In 
biodistribution studies mass-time deposition in tissues and organs is measured and target 
organs are identified. Consumer, patient and worker exposure can occur via inhalation and 
oral, dermal and intravenous routes, for instance. 
2.1.2.1 Intravenous exposure 
Intravenous exposure represents 100 % bioavailability and serves as a reference for the 
biokinetics of nanoparticles via other mechanisms, such as inhalation, dermal or oral routes. 
In addition, it is the most likely potential route of exposure for nanoparticles as therapeutic 
agents, as absorption is often negligible via other routes.  
When nanoparticles are administrated intravenously, the majority of them are usually 
distributed to organs belonging to the mononuclear phagocyte system (MPS), especially the 
liver and spleen (Saba et al., 1969). In the mononuclear phagocyte, system nanoparticles are 
captured by phagocytic cells like macrophages and Kupffer cells. Nanoparticles are also 
distributed to other organs, but to a lesser extent. In addition, uptake by cell types other than 
phagocytic cells has been observed, as well as attachment to cell surfaces and deposition in 
the extracellular space (Demoy et al., 1999; van Schooneveld et al., 2008; Hirn et al., 2011; 
Keene et al., 2012).  
As soon as the nanoparticles are in contact with blood, proteins and other biomolecules 
instantly begin competing over binding to the nanoparticle in a process called opsonisation, 
leading to the formation of a protein corona (Nel et al., 2009; Docter et al., 2015). The 
protein corona changes the biological property of the nanoparticles and modifies the 
recognition and phagocytosis by macrophages (Docter et al., 2015). Hydrophobic and 
charged particles appear to be opsonised more easily than uncharged hydrophilic 
nanoparticles such as PEG coatings. Coating with PEG tends to minimize opsonisation and 
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uptake by the MPS (Bazile et al., 1995; Schottler et al., 2016). In fact, opsonisation affects 
distribution and uptake mechanisms (Ogawara et al., 2001; Tenzer et al., 2013). 
To reach the tissue, nanoparticles have to be distributed by the blood circulation to the organs 
and locally cross the endothelium (Figure 1). To cross the endothelium the nanoparticles have 
to pass between the endothelial cells or through them (Setyawati et al., 2015). To keep the 
barrier function, endothelial cells are linked to each other with junctions (Michel et al., 1999; 
Mehta et al., 2006). The junctions are tight in the brain, but in organs like the liver and bone 
marrow there are fenestrations, which facilitate translocation into tissue. Some nanoparticles 
have the ability to interact with junctions, which increases the transport to tissue (Moyes et 
al., 2007; Lin et al., 2012). During inflammation, tight junctions are loosened and 
endothelium gaps are formed in the normally continuous endothelium coated with glycocalyx 
i.e. a hairy coating made of glycoprotein-polysaccharide that covers the luminal side of the 
endothelium (Levick, 2010). 
Transcellular passage of nanoparticles can occur by different mechanisms, such as 
endocytosis and diffusion, see Figure 1. Endocytosis requires energy and includes processes 
like phagocytosis, caveolae-mediated or clathrin-mediated endocytosis and macropinocytosis 
with diversified characteristics (Nel et al., 2009; Canton et al., 2012). The uptake to cells 
involves several steps, such as transport toward the surface, recognition by cells, binding and 
cell internalization (Jin et al., 2009; Ohta et al., 2012; Feliu et al., 2016b). The capacity for 
endocytosis in capillaries is higher in organs like liver and bone marrow (Sarin, 2010). These 
organs are called sinusoid reticuloendothelial blood capillaries (Saba, 1970). Recently a new 
pathway for translocation of nanoparticles over the endothelium has been observed, called 
membrane nanotubes, which are formed between cells with diameters ranging between 50-
200 nm in average (Rehberg et al., 2016). 
 
Figure 1. Translocation pathways over the endothelium. 
It has long been known that the uptake capacity of the liver can be suppressed by saturating 
the Kupffer cells or by depleting opsonic factors (Biozzi et al., 1953; Bradfield, 1980; Illum 
et al., 1986). When phagocytosis in the liver is suppressed, accumulation of particles 
increases in spleen, lung, kidney and bone marrow (Biozzi et al., 1953; Illum et al., 1987). 
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The saturation may be due to either the equilibrium between endocytosis and exocytosis or 
the capacity limitation of the cells.  
The fate within the cell varies depending on the uptake process. In the studies where 
internalization of nanoparticles was evaluated, most nanoparticles were found in vesicles, 
lysosomes and endosomes (Moghimi, 2002; Lee et al., 2009a; Wang et al., 2010; Morais et 
al., 2012). In the lysosomes and phagosomes, nanoparticles are subjected to an environment 
with enzymes, reactive oxygen species and reduced pH. Many nanoparticles are stable, but in 
some cases coatings and labelling may dissolve in this environment (Briley-Saebo et al., 
2004; Knop et al., 2010; Mahon et al., 2012).   
The macrophages of the MPS are heterogeneous and differ slightly between species, pointing 
to a potential difference in the ability to recognize and capture nanoparticles (Gordon et al., 
2005; Verschoor et al., 2012). Furthermore, the pool size and kinetic parameters, such as rate 
of migration, rate of production and mean turnover time of macrophages, may vary between 
tissues (van Furth, 1989). In addition, repeated exposure can suppress and stimulate the MPS 
depending on the dose, dosing frequency and dosing duration (Biozzi et al., 1953). 
Nanoparticles are discharged from cells by diffusion (only small nanoparticles), exocytosis or 
due to cell death. Observation of concentration of gold nanoparticles to fewer cells suggests 
that clustering and cannibalism between Kupffer cells can occur (Sadauskas et al., 2009). 
Clearance from the body by way of urine and faeces via bile is reported. Clearance to urine 
has been argued to be limited to small substances (< 40 kDa) and nanoparticles (< 8 nm), but 
exceptions have been reported (Choi et al., 2007; Lacerda et al., 2008; Nel et al., 2009). 
2.1.2.2 Inhalation 
Dust- and airborne nanoparticles can be inhaled and end up in the respiratory system. The 
respiratory system with its conduit airways is organized in a complex branching tree 
structure, which can be divided into upper respiratory tract, tracheobronchial region and 
alveolar region (Snipes, 1989; Oberdorster et al., 2005b). When nanoparticles are inhaled 
they will be deposited in this system, with locally enhanced deposition in airway branches, 
so-called ―hot spots‖ (Brain et al., 1976; Snipes, 1989; Balashazy et al., 2003). 
Where nanoparticles are deposited and to what extent depends on their properties, the 
exposure conditions and the physiological and anatomical properties of the exposed species 
(Snipes et al., 1983; Daigle et al., 2003; Kreyling et al., 2013). The three most commonly 
used mechanisms to describe deposition are impaction, sedimentation and diffusion (Anjilvel 
et al., 1995; Hofmann, 2011). Because of the extremely small sizes, nanoparticle deposition 
is mainly driven by diffusion, by which the particles are transported deeper into the lung than 
larger particles. Larger particles are primarily deposited by impaction in the upper airways (> 
1.5 µm) and by sedimentation in the tracheobronchial region (> 0.5 µm). Other mechanisms 
for deposition are turbulence, interception, electrostatic deposition, and thermophoretic and 
diffusiophoretic forces, but their impacts on deposition on nanoparticles are, thus far, not 
well-addressed in modelling (Guha, 2008).  
Once deposited, nanoparticles are in contact with mucus and lining fluids where they may 
submerge and react with ions, surfactants and proteins. As a result, those particles may 
agglomerate, degrade, migrate or become engulfed by lung cells (Schulze et al., 2011).  
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Deposited nanoparticles can be cleared. In the upper respiratory tract, they are removed by 
coughing, sneezing and swallowing. In the tracheobronchial region, the main mechanism is 
by the mucociliary escalator to the larynx and further transport into the gastrointestinal tract 
(Oberdörster, 1988). In the alveolar region, nanoparticles are captured by alveolar 
macrophages, which migrate to the tracheobronchial region for mucociliary clearance or to 
mediastinal lymph nodes (Geiser et al., 2005; Choi et al., 2010). The retention time in the 
alveolar region is longer than in the tracheobronchial region (Oberdörster, 1988).  
Increasing the dose may overload the system and impair macrophage clearance. For poorly 
soluble particles impaired clearance has been suggested to start when 6 % or more of the 
alveolar macrophages volume in rats is occupied by particles (Morrow, 1988; Morrow et al., 
1996). How to extrapolate this to human exposure limit values is debated (Pauluhn, 2014; 
Morfeld et al., 2016). During an overload situation an inflammation may result in an 
increased leakage of particles to the lymph nodes (Tran et al., 2000). Alveolar macrophages 
are long-lived, but new ones can be recruited, especially during inflammation. 
From the lining fluid, nanoparticles can migrate to the epithelium surface and translocate into 
either the blood circulation or the lymphatic system. How nanoparticles translocate is not 
fully understood. Translocation through cells can be active or passive, whereas transport 
between cells is restricted to nanoparticles that fit in the cell gaps or interact with cell 
junctions, or occurs during inflammation when junctions are disrupted (Muhlfeld et al., 
2008). Another suggested mechanism is transport with the help of macrophages and dendritic 
cells, especially to the lymphatic system (Harmsen et al., 1985). Interestingly, nanoparticles 
have been reported to re-enter the lung (Semmler-Behnke et al., 2007). Translocation of 
nanoparticles into extrapulmonary organs is low in general and, much like intravenously 
injected nanoparticles, inhaled nanoparticles tend to target the mononuclear phagocyte system 
(Kermanizadeh et al., 2015; Johanson et al., 2016). However, increased inhaled doses 
increase transport to lymph nodes (Tran et al., 2000; Keller et al., 2014).  
Nanoparticles deposited in the nose region during nasal breathing can be swallowed, sneezed 
and coughed out. In addition, translocation into the brain via axons in olfactory nerves has 
been demonstrated (DeLorenzo, 1970; Elder et al., 2006). Olfactory uptake of magnesium 
oxide nanoparticles resulted in inflammatory changes in the brain (Elder et al., 2006). Size 
influences deposition and translocation. 
2.1.2.3 Dermal exposure 
Nanoparticles are applied on the skin intentionally via cosmetics, but also unintentionally via 
products not designed for skin contact. In textiles, nanoparticles of silver and other metals are 
added to achieve properties referred to as, e.g., anti-bacterial, water-repellent, UV-absorbing, 
and wear and tear resistant. Nanoparticles can also be found in products such as motor oil, 
fuel catalysts and cleaning products, with potential consumer and occupational exposure 
(Poland et al., 2013). 
Skin is a large organ (15% of the body weight) and prevents loss of water and heat as well as 
protects the body from mechanical, biological and chemical hazards. It consists of three 
layers; hypodermis, dermis and epidermis (Johanson et al., 2008). The outermost layer of the 
epidermis, stratum cornea, provides the major barrier for nanoparticle uptake. To get into 
systemic circulation nanoparticles have to penetrate the stratum cornea, especially via hair 
follicles, sweet glands or intra/intercellular routes. Passage via hair follicles and sweet glands 
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is the most probable route for nanoparticles. Intercellular routes are limited to small 
nanoparticles and intracellular routes are primarily accessible for chemical substances and 
ions (Johanson et al., 2016).  
The permeability of nanoparticles through intact skin is small but several factors may 
increase the extent of uptake. (Tinkle et al., 2003; Johanson et al., 2008; Filon et al., 2011; 
Filon et al., 2015) These include anatomical site (skin thickness), skin humidity, temperature, 
barrier integrity, mechanical flexion, nanoparticle properties, contaminants in nanoparticles, 
and dissolution of nanoparticles. Wounds, detergents, organic solvents and skin burns may 
destroy the integrity of the skin and provide breached barrier function to nanoparticles. 
Dissolution of nanoparticles results in release of chemical substances and ions with increased 
permeability over nanoparticles (Filon et al., 2015; Midander et al., 2016). With decreased 
size the probability for uptake increases (Filon et al., 2015; Johanson et al., 2016). Uptake 
through intact skin has been demonstrated for sizes smaller than 4 nm, and penetration via 
follicles and sweet glands seems to be possible for sizes up to 20 nm. On the other hand, 
penetration and permeation of sizes above 45 nm probably only take place in severely 
damaged skin (Filon et al., 2015).  
2.1.2.4 Oral exposure 
Oral exposure to nanoparticles may result from ingestion of food, fluids or drugs (Etheridge 
et al., 2013; McCracken et al., 2016). In addition, exposure can also occur through 
unintended swallowing of products containing nanoparticles or ingestion of nanoparticles 
released from products during interactions such as licking, sucking and chewing. Inhaled 
airborne particles also end up in the gastrointestinal tract when deposited non-respiratory 
fractions or mucociliary cleared particles are swallowed (Oberdörster, 1988; Snipes, 1989). 
Systemic uptake via oral exposure is an attractive distribution pathway for nutrients and 
drugs. Several efforts have been made to improve absorption by modification of size, shape 
and surface properties (Mei et al., 2013). However, reported absorption differs significantly 
between studies, where several studies could not demonstrate any uptake and other studies 
measured uptake of several per cent of administered dose (Johanson et al., 2016). 
In the gastrointestinal tract, the nanoparticles interact with the local environment, including 
food components, which affect the uptake and the toxicity (Cao et al., 2016). During this 
interaction proteins and biomolecules adhere to the nanoparticle surface forming a corona 
(Docter et al., 2015). So far, only a few in vitro studies have evaluated the impact of the 
corona on uptake, but the results suggest increased absorption (Di Silvio et al., 2016). 
Increased absorption and toxicity can also be a result of dissolution of the nanoparticles, as 
reported for zinc oxide nanoparticles (Wang et al., 2014). On the other hand, nanoparticles 
can also affect the nutrient uptake by either damaging the intestinal cells or changing the 
expression in nutrient transporters (Mahler et al., 2012; Dorier et al., 2015).  
To enter the body, nanoparticles have to overcome two barriers: the mucus and the 
epithelium. The first barrier, the mucus, is a sticky, hydrophobic and negatively charged gel 
wherein nanoparticles can be trapped (Lai et al., 2009). The continuous renewal of mucus 
transports trapped nanoparticles distally to faeces. If nanoparticles manage to migrate through 
the mucus, they have to pass the second barrier, the epithelium, to reach the systemic 
circulation (des Rieux et al., 2006). The dominant cell type in the intestinal epithelium is the 
enterocyte, but it does not seem to account for the major transcellular transport, though 
uptake has been demonstrated. Instead, transport takes place in the less numerous M-cells in 
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the Peyer’s patch. M-cells account for approximately 1 % of the intestinal epithelium cell 
population and are part of the mucus-associated lymphoid tissues. From the interstitial space, 
nanoparticles can translocate into blood circulation and lymph systems for further distribution 
to distal organs and tissues (Li et al., 2010; Roger et al., 2010). 
2.2 PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELLING 
PBPK models provide information about mass-time profiles of individual tissues and organs 
and use mathematical equations to describe how substances are absorbed, distributed, 
metabolized and excreted over time (IPCS, 2010; Krishnan et al., 2010; Johanson, 2014). By 
incorporation of knowledge about anatomy, physiological mechanisms and substance 
kinetics, the mathematical model can predict the internal dose of a substance based on 
information about external exposure. PBPK models also allow interspecies 
extrapolation,where findings from animals can be scaled up to humans without additional 
testing. In fact, PBPK models are used for drug development, animal toxicity test designs and 
human health risk assessments. Moreover, PBPK models are useful for extrapolation between 
species, doses and routes of exposure.  
A PBPK model is structured into compartments that represent organs (IPCS, 2010; Krishnan 
et al., 2010; Johanson, 2014). Each compartment is organized in a biologically relevant 
position and compartments are interconnected through the mass transport between them. 
How many the compartments are and how they are structured is determined by the intended 
use of the model and knowledge about the substance(s) of interest. Typically, the model 
includes separate compartments for target tissues, tissues with biotransformation and 
clearance, and storage tissues. To avoid over-parameterization and reduce computation time, 
the complexity of the model should be minimized. Pooling of organs is one way of doing this, 
where tissues with similar properties, such as blood flow and partitions, are lumped into a 
joint compartment.  
Substances enter the system by exposure routes such as inhalation, injection into blood, 
dermal contact and/or digestion. To reach the circulatory system for further transport to distal 
organs, substances may need to pass barriers. Transport over barriers occurs by active or 
passive processes. Once absorbed, substances are distributed to organs via the circulatory 
system. In the organs, substances move into the tissue, a phenomenon often described by 
mass-balance differential equations of the first order with either perfusion- and or diffusion-
limited processes. Distribution between blood and tissue may for substances be described by 
a partition coefficient, which assumes a well-stirred compartment in a quasi-steady state. 
Clearance occurs from organs such as the liver and kidney and may involve metabolism. 
When processes involve saturation they can often be described using Hill equations.  
The model includes parameters which are physiologically based or substance-specific and are 
typically derived from scientific literature, experiments or estimated by the model (IPCS, 
2010; Krishnan et al., 2010; Johanson, 2014). Body and organ weight, blood flow, and 
ventilation rate are examples of physical parameters, whereas partition and metabolic rates 
are examples of substance-specific parameters.  
Optimizing the performance of a PBPK model is an iterative process (IPCS, 2010; Krishnan 
et al., 2010; Johanson, 2014). The process starts with comparing predictions with 
experimental data from biodistribution studies and then refining the model, if they do not 
cohere. Refinements involve adjustment of model structure and/or optimization of parameters 
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to provide the best fit between predictions and experimental observations. The process is 
called calibration. During validation, the performance of the calibrated model is evaluated by 
comparing the model predictions with external data, i.e., data not used for calibration. Model 
performance is evaluated by visual inspection and/or goodness-of-fit criteria, such as, 
coefficient of determination (R
2
), maximum log-likelihood and the Akaike information 
criterion. 
To identify model parameters that influence model outcome the most, sensitivity analyses are 
carried out (IPCS, 2010; Krishnan et al., 2010; Johanson, 2014). This is important as a small 
change in a sensitive parameter will have a large impact on the accuracy of the output. 
Sensitivity analysis is a quantitative evaluation, where a change in response/output is 
measured as a result of a change in an input parameter. Changing one parameter at a time is 
called local sensitivity analysis. Local sensitivity analysis has the limitation that covariates 
and interactions between parameters cannot be assessed. By varying multiple parameters 
simultaneously such relationships can be assessed. This is referred to as a global sensitivity 
analysis. However, a global sensitivity analysis requires a powerful computer processor, 
which often limits its usability.  
 PBPK model for intravenously injected nanoparticles 2.2.1
An increasing number of PBPK models for nanoparticles injected intravenously have been 
published; most of them aim to describe experimental data (Table 1).  
Table 1. Summary of PBPK models for rodents injected intravenously with nanoparticles. 
Type of  
nanoparticles 
Model  
parameter 
Model  
evaluation 
References 
 
P
ar
ti
ti
o
n
 
P
e
rm
e
ab
ili
ty
 
P
h
ag
o
cy
to
si
s 
External 
validation 
Sensitivity 
analysis Goodness of fit 
 
PT-ODN x x - - - Visual (Peng et al., 2001) 
Quantum dots x  -  -  - 
b
 Visual (Lin et al., 2008) 
Quantum dots x  -  - x - Visual (Lee et al., 2009b) 
Silver x  - x
a
  - - Visual (Lankveld et al., 2010) 
MINP x x  - x Local Visual (Opitz et al., 2010) 
Gold dendrimers x x x
a
  - Global Visual (Mager et al., 2012) 
PLGA x x  -  - Local R
2
 (Li et al., 2012) 
Silver x x x x Local Visual (Bachler et al., 2013) 
Titanium dioxide x x x x Local Visual (Bachler et al., 2015b) 
PAA x x x  - Local R
2
 (Li et al., 2014) 
Gold x x x x Local R
2
 (Lin et al., 2015a) 
Block co-polymer x  -  -  - Local Visual (Gilkey et al., 2015) 
Titanium dioxide x  -  -  - - AIC + BIC (Elgrabli et al., 2015) 
Zinc oxide  x  -  -  - Local MAPE (Chen et al., 2015) 
Gold x x x x - R
2
 (Lin et al., 2016) 
Gold, titanium dioxide, 
PAA, PAA-PEG 
x x x - Local R
2
, PBPK indices (Carlander et al., 2016) 
a Uptake to a storage compartment in tissue 
b Performed but no details provided 
Abbreviations: AIC - Akaike information criterion, BIC - Bayesian information criterion, MAPE -  mean absolute 
percentage error, MINP – Magnetic imaging nanoparticles, PAA – Polyacrylamide, PLGA - poly(lactic-co-glycolic 
acid), PT-ODN - phosphorothioate oligonucleotide, R
2
 - coefficient of correlation. 
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The early models followed the structure used for xenobiotics, but they did not adequately 
explain the more complex kinetics exhibited by nanoparticles. To improve the models, 
additional factors of relevance for nanoparticles have been incorporated, such as phagocytosis 
and permeability restrictions (Peng et al., 2001; Li et al., 2014). Time- and size-dependent 
phagocytic rates and time-dependent partitioning are other examples of modifications 
implemented into PBPK models for nanoparticles (Lin et al., 2008; Bachler et al., 2013; 
Chen et al., 2015; Lin et al., 2015a). Evaluation of the performance of models has frequently 
been done by visual inspection, but statistical methods such as coefficient of correlation and 
the Akaike criterion have also been used. Validations of models with external data and to 
additional species have not always been performed, which probably reflects the lack of 
suitable data for modelling. So far, most models are limited to a single type of nanoparticles 
and models for repeated and life-long exposure are not yet available. 
 PBPK model for inhalation of nanoparticles 2.2.2
The number of published PBPK models for inhaled nanoparticles is limited and their 
usability is restricted to a few types of nanoparticles, see Table 2. The structure differs widely 
between the models, for example as regards the structure of the lung and the number of extra 
pulmonary organs. The respiratory system is described by one or several compartments and 
some models include alveolar macrophages. In the lung, the majority of the nanoparticles are 
cleared via uptake by alveolar macrophages and mucociliary clearance, described in models 
with separate transport processes or as a joint process. From the lung, a fraction of deposited 
nanoparticles is transported to the interstitium, lymph system and/or blood circulation. In 
addition, some models address uptake to the brain via the olfactory system. When 
nanoparticles are cleared from the lung via mucociliary clearance the majority of the models 
assume that nanoparticles reach the gastrointestinal tract and/or get cleared by cough or 
sneezing.  
Table 2. Summary of PBPK models for inhalation of nanoparticles and compartments 
included in the model structure. 
Type of 
nanoparticles 
Number of  
compartments in 
Compartments in model References 
 
Extra 
pulmonary 
organs
a
 
Breathing 
system
b
 Olfactory Lymph AM PC GIT  
 Aluminium silicate 3 4 - x - - x (Snipes et al., 1983) 
Iridium 9 6 x x x x
c
 x (MacCalman et al., 2009) 
Carbon 22 2 - - - - x (Pery et al., 2009) 
Ag, Au, QD, PS, carbon 11 2 - x - - x (Li et al., 2011) 
Iridium, Co3O4, Tb2O3 4 12 x x x - - (Kolanjiyil et al., 2013) 
Ag 10 1 - - - x x (Bachler et al., 2013) 
Gold 6 2 - - X
d
 - - (Bachler et al., 2015a) 
Iridium and silver 10 6 x x x x
c
 x (Sweeney et al., 2015) 
Nanoceria 10 7 x  - x x x (Carlander et al., 2016) 
a All organs and tissues outside the breathing system 
b Compartments for deposition as upper respiratory tract, tracheobronchial region,  alveolar region and sub-
compartments such as AM, lung interstitium and lung lymph nodes 
c Uptake to a storage compartment in tissue 
d Not expressed as uptake to AM, but similar to uptake to AM 
Abbreviations: Ag - silver, AM - alveolar macrophages, Co3O4 - cobolt oxide, GIT - gastrointestinal tract, PS - 
polystyrene, QD - quantum dots, Tb2O3 - terbium oxide 
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Building a PBPK model for inhalation information regarding deposition in the lung is 
essential. To get information about deposition in the respiratory system, deposition models 
and/or experimental data are used. Several computational models and approaches are 
available to describe and calculate deposition of particles in the lung (Hofmann, 2011). 
Deposition models can be divided into two categories depending on the intended use: whole-
lung or local deposition models. The whole-lung model provides information about 
deposition in the entire respiratory system, whereas the more complex and computer-intense 
local models so far only address local deposition in the upper respiratory tract. In PBPK 
modelling, whole-lung deposition models are more frequently used than local deposition 
models and the most commonly used model is probably the Multi-Path Particle Dosimetry 
(MPPD) model (Anjilvel et al., 1995; RIVM, 2002).  
The MPPD model is an open access software that calculates deposition and clearance of 
mono-dispersed and poly-dispersed particles in the range 0.01 µm to 2 µm in the respiratory 
system of humans and animal species such as rats, mice, rabbits and pigs. A fraction of the 
particles from external exposure are filtrated in the nose and mouth, described by an 
empirical efficiency function in the model. Once inhaled, particles will be deposited and the 
deposition is theoretically calculated by diffusion, sedimentation and impaction, calibrated 
and validated with external data. The structure of the lung is represented either by a single 
symmetric tree or by a multi-path branching, as selected by the user. The asymmetric 
branching pattern of the multi-path model has been derived from actual measurements on 
lung casts. To receive information about deposition and clearance, the model requires input 
data from the user on a breathing scenario and particle properties. The output presents 
calculations on total, regional (head, tracheobronchial, and pulmonary) and lobar fractional 
deposition. Regional deposition values from the MPPD model have been used as input for 
PBPK models, but the MPPD model has not yet been incorporated as part of the model. 
 PBPK model for mixed exposure routes  2.2.3
Only three PBPK models for mixed exposure routes to nanoparticles have been published so 
far (Li et al., 2011; Bachler et al., 2013; Bachler et al., 2015b). These models include 
inhalation, dermal contact and/or digestion of nanoparticles.  
One of the models is framed as a general PBPK model and covers inhalation, digestion and 
intravenous injection of different types of nanoparticles and species (Li et al., 2011). To 
predict biokinetics, first-order mass transfer rates to and from organs in well-mixed 
compartments are used, but the model does not account for, e.g., diffusion-limited processes, 
phagocytosis, degradation or size-dependent deposition in the lung. Pooled data from in vivo 
studies on various types of nanoparticles and exposure conditions and routes have been used 
for calibration. 
The other two models have similar model structures; one is designed for silver ions and silver 
nanoparticles (15 nm to 150 nm) and the second describes the biokinetics of titanium dioxide 
nanoparticles (Bachler et al., 2013; Bachler et al., 2015b). Both models include the same 
organs, use permeability-restricted transport processes and allow uptake of nanoparticles 
directly from blood to phagocytes in liver, spleen and lung. In addition, both models use first-
order mass transfer rates and have been optimized with rodent and human biokinetic data. On 
the other hand, they differ in that the silver model has a substructure for ions and a size-
dependent uptake rate in phagocytic cells, which the titanium dioxide model does not.  
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In short, all three models are reported to perform well, but as no clear relationships between 
nanoparticle properties, exposure conditions and model parameters are provided their 
usability for risk assessment is limited. Consequently, extrapolations between nanoparticle 
types, species, doses and routes of exposure are not yet possible.  
 Dissolution in PBPK modelling 2.2.4
So far, only one PBPK model for nanoparticles includes dissolution. This models describes 
the biokintics for silver nanoparticles and the dissolution of silver into silver ions and 
glutathione bounded silver (Bachler et al., 2013).  
Dissolution is a process that makes metallic nanoparticles transform into ionic species and by 
which their properties and abundance are altered. The dissolution rate and characteristics of 
dissolved species depend on the characteristics of the nanoparticles, such as chemical 
composition, size, shape, crystallinity, surface coatings and agglomeration, as well as on the 
surrounding media and exposure conditions, such as dose, composition, ion strength, pH, and 
temperature (Costa et al., 2001; Mishra et al., 2011; Utembe et al., 2015; Feliu et al., 2016a). 
If the dissolution rate is low, the risk for bioaccumulation increases, but if the dissolution rate 
is high, substances can migrate and dissolve into surrounding media. Dissolved and 
solubilized substances can, in fact, have different properties, toxicity and biokinetics 
compared with the nanoparticles, and consequently requires consideration in PBPK 
modelling (Molina et al., 2014; Sabella et al., 2014).  
Dissolution of metals involves release of ions. Some ions complex bind to substances in the 
surrounding environment, which sometimes results in generation of new types of 
nanoparticles as observed for silver and cerium (Loeschner et al., 2011; van der Zande et al., 
2012; Graham et al., 2014). Consequently, the abundance in tissue can be a mixture of 
nanoparticles, complex bounded ions, and free ions, making analysis challenging and the 
biokinetics complex.  
Inclusion of dissolution in PBPK models requires experimental data on the biokinetics of 
nanoparticles as well as on the dissolved species. However, most biodistribution studies 
performed on metallic nanoparticles have only used elementary analysis such as ICP-MS and 
atomic absorption spectroscopy to measure the organ burden, and hence cannot distinguish 
between different forms of metals (Johanson et al., 2016). 
Modelling dissolution kinetics of nanoparticles is under development but such models have 
not yet been implemented in PBPK models for nanoparticles (Costa et al., 2001; Mishra et 
al., 2011; Utembe et al., 2015). These dissolution models are often based on experience from 
larger particles and assume release from surfaces. To describe dissolution mathematically, 
zero-, first-, or second-order kinetics with release rate constants dependent on surface area, 
volume and diffusion have been tested. The majority of existing models for nanoparticles are 
related to particles with high dissolution rates and in vitro conditions. 
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3 AIMS 
The PBPK simulations were performed assuming that the nanoparticles are inert, i.e. do not 
dissolve or degrade in the body. When modelling the experimental data it seemed that the 
biokinetics might be better explained by introducing dissolution in the PBPK model. 
Therefore, an additional aim was introduced, i.e. to evaluate dissolution of stable 
nanoparticles in the presence of macrophages.  
The specific aims were: 
1. To develop and verify a PBPK model for stable nanoparticles that were 
administered intravenously (Papers I, II and III). 
2. To extend the PBPK model to account for other routes of exposures (Papers III 
and IV). 
3. To evaluate the stability of gold nanoparticles when exposed to macrophages 
(Paper V).  
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4 MATERIALS AND METHODS 
This section summarizes the materials and methods used for this thesis (Papers I-V). The first 
part relates to the development of nano PBPK models and presents how the PBPK model was 
evaluated and modified to describe biokinetics of nanoparticles considered inert, such as 
polyacrylamide (PAA), gold (Au), titanium dioxide (TiO2) and cerium dioxide (nanoceria 
and CeO2) when delivered to rats via intravenous administration, inhalation, instillation and 
ingestion (Papers I-IV). The second part describes a follow-up study from a finding in Paper 
II related to the dissolution of gold by macrophages (Paper V).    
4.1 PBPK MODELLING OF NANOPARTICLES 
The process used to develop PBPK models for nanoparticles considered inert and 
administered intravenously or via inhalation, instillation and ingestion into rats is described in 
Figure 2 and summarized in paragraphs 4.1.1 to 4.1.5. More detailed information can be 
found in Papers I-IV.  
 
Figure 2. Overview of the modelling process in this thesis. 
 Development of a nano PBPK model for intravenous exposure  4.1.1
As a first step a PBPK model for nanoparticles injected intravenously into rats was developed 
(Paper I). Conceptually, the model represents systemic exposure without involvement of 
absorption barriers. The model was designed based on experimental data on tissues/organs 
and body fluids analysed for polyethylene glycol-coated polyacrylamide (PAA-PEG) 
nanoparticles, combined with general information about the biokinetic behaviour of 
nanoparticles.  
To build a conceptual PBPK model for inert nanoparticles injected intravenously, 
experimental data from a published study on PAA-PEG was used (Wenger et al., 2011). The 
PAA-PEG study was designed for PBPK modelling and hence contained relevant data, i.e., 
data from multiple organs, multiple post-injection follow-up times, and total recovery, see 
Table 4. The PAA-PEG nanoparticles were administered with a bolus intravenous dose to 
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five groups of rats. Organs were collected and analysed with liquid scintillation counting of 
C
14
.  
The model contains ten compartments: arterial and venous blood, liver, spleen, lung, kidney, 
heart, brain, bone marrow and other organs. The lymphatic system was not included in the 
model, even though data was available and this probably is a common pathway for 
nanoparticles. However, adding the lymph system to the model would introduce increased 
model complexity. In addition, model optimization had to be carried out on values that 
contributed to a negligible amount of the total body burden (< 0.1 %).   
Each organ compartment is subdivided into three sub-compartments: capillary blood, tissue 
and phagocytic cells, with venous and arterial blood described by two sub-compartments: 
blood and phagocytic cells. The compartments are interconnected with each other via blood 
flow and organized in physiological order. Excretion to faeces takes place from liver tissue 
and to urine from capillary blood via the kidneys.  
The model parameters consist of nanoparticle-independent parameters and nanoparticle-
dependent parameters, summarized in Table 3. Values on physiological parameters were 
primarily taken from experiments and secondarily collected from the literature (Brookes, 
1967; Bernareggi et al., 1991; Brown et al., 1997; Travlos, 2006). Data on the nanoparticle 
uptake capacity of phagocytic cells in organs were sparse and therefore experimental data 
were used as a basis for model estimation of these parameters. All nanoparticle-dependent 
parameters were fitted.  
Table 3. Summary of model parameters in PBPK model for intravenous administration of 
nanoparticles. 
Nanoparticle-independent Nanoparticle-dependent parameters 
 Bodyweight 
 Cardiac output 
 Fraction of cardiac output to 
tissue/organ 
 Fraction of total bodyweight for 
different tissues 
 Fraction of blood in different tissues 
 Rate of clearance in urine (CLu) 
 Rate of clearance in faeces (CLf) 
 Rate of uptake by phagocytic cells (Kab0) 
 Rate of uptake by phagocytic cells in spleen 
(Ksab0) 
 Uptake capacity of phagocytic cells in different 
tissues (Mcap,i) 
 Fraction of residual blood in brain 
 Fraction of residual blood in tissue 
 Tissue:blood partition coefficient (P) 
 Coefficient of permeability from blood to the 
liver, spleen, lung, kidney, heart and brain (Xfast) 
 Coefficient of permeability from blood to other 
organs (Xrest) 
 Coefficient of permeability from blood to the 
brain (Xbrain) 
 
The transport of nanoparticles from blood to tissues/organs is described by flow- and 
diffusion-limited processes, and in the PBPK model controlled by the coefficients for 
permeability and fractions of cardiac output to organs. There are three permeability 
coefficients in the model. The first is used for fast perfused organs (Xfast): liver, spleen, lung, 
kidney, heart, and bone marrow, while the second is designed for brain (Xbrain) and the third is 
utilized for other organs (Xrest). The permeability coefficient in brain is set to zero, based on 
the assumption of a tight and impermeable blood-brain barrier. 
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During the development of the model, inclusion of a tissue:blood partition coefficient in the 
PBPK model was needed to describe the biokinetics of PAA-PEG nanoparticles. This is 
assumed to reflect the changes in the corona formed on the particles due to differences in 
composition of blood and interstitial fluid, causing PAA-PEG to have a preference for blood 
over tissue (Lundqvist et al., 2008; Monopoli et al., 2012). Despite differences in 
composition of interstitial fluids between tissues, the tissue:blood coefficient kept the same 
value for all organs/tissues. 
In tissue, the phagocytic cells engulf a fraction of the nanoparticles and eventually the 
phagocytic cells get saturated. The saturation process is controlled by the balance between 
uptake and exocytosis rates and the maximum uptake capacity of phagocytic cells in tissues. 
The uptake rate is described as a function of maximum uptake capacity and decreases as the 
phagocytic cells reach saturation. Moreover, the maximum uptake capacity in each organ is 
assumed to reflect the density of phagocytic cells in tissue.   
According to the study design for PAA-PEG, the blood vessels were not rinsed before 
harvesting of organs (Wenger et al., 2011). Consequently, residual blood may have remained 
in organs. In fact, the levels in brain could be explained by implementation of a coefficient 
that assumes that the capillary blood in organs was not entirely removed when organs were 
harvested. In the model, two coefficients accounting for fraction of residual bloods in organs 
were introduced and fitted to observed data, one constant for the brain and another constant 
for all other organs.  
 Expansion of the PBPK model to other nanoparticles given 4.1.2
intravenously 
As a next step, the model was expanded to other inert nanoparticles (Paper II).  
Data for modelling were retrieved from the literature to evaluate if the model in Paper I could 
describe the biokinetics of other considerable inert nanoparticles intravenously injected in 
rats. To find such data, a literature review was carried out in SciFinder, PubMed, Google 
Scholar and Web of Science and reference lists in papers were scrutinized. Information about 
nanoparticle properties, study designs and test results were extracted from the collected 
studies (> 200 data sets). To select data sets for modelling, the following criteria were used:  
1. The nanoparticle and its label should not be soluble or degradable.  
2. The dose should be reported in quantitative units. 
3. The amount or concentration in organs should be reported or possible to extract 
from figures in quantitative units. 
4. The organs analyzed should include blood, liver, spleen and at least two additional 
organs or tissues. 
5. The observation period post-injection should be at least 24 h, with at least four 
sampling times. 
6. The total recovery in all reported tissues/organs monitored must be at least 25 % 
of the injected dose. 
Using the above criteria, three data sets on polyacrylamide, gold and titanium dioxide 
nanoparticles were found, in addition to the data set in Paper I. Numerical data were reported 
in the papers for coated and uncoated polyacrylamide and for titanium dioxide, but data on 
gold had to be extracted from figures and the bodyweight estimated based on the strain and 
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age of rats used. Study characteristics of the four data sets in Paper I and Paper II are 
summarized in Table 4.  
The model structure is the same as in Paper I, but the model parameter describing uptake 
capacity in phagocytic cells in tissues (Mcap) has been modified and the grouping of organs 
correlated to the three blood-organ coefficients of permeability (Xfast, Xrest and Xbrain) were 
elaborated.  
In Paper I, it was assumed that all phagocytic cells behaved the same but that their abundance 
varied between organs. The parameter (Mcap) was defined as the uptake capacity of 
phagocytic cells per gram tissue and hence independent (number of phagocytic cells per gram 
tissue) and dependent (uptake capacity of an individual phagocytic cell) of nanoparticle 
properties. To separate the nanoparticle-dependent part from (Mcap), (Mcap) was divided into 
two coefficients in Paper II. The first coefficient described the number of phagocytic cells per 
gram tissue (Ncap, tissue) and the second described the uptake capacity of an individual 
phagocytic cell (McapPC). This separation made it possible to compare uptake capacity of 
phagocytic cells predicted by the model with experimental data from in vitro studies.  
There are three blood-organ coefficients of permeability in the PBPK model. Each coefficient 
is connected to a set of organs. The grouping of organs was elaborated to explore dependence 
on permeability in endothelium and presence of phagocytic cells in direct contact with blood. 
Three different groupings were tested. The first grouping was the same as in Paper I. In the 
second, the (Xfast) was assigned to spleen and liver. In the third, the (Xfast) was reserved for 
liver, spleen and bone marrow. 
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Table 4. Summary characteristics of data sets for nanoparticles intravenously administered to rats, used to develop the nanospecific PBPK model in Paper I, Paper II 
and Paper III. 
Material PAA PAA  Gold TiO2  CeO2 CeO2 CeO2 
Trade name Synthesized Synthesized Synthesized Degussa P25 Synthesized Synthesized Synthesized 
Coating PEG  No CTAB No Citrate Citrate Citrate 
Shape Sphere Sphere Rod Sphere Polyhedral Polyhedral Cubic 
Size (nm) D:31 D:31 L:56 D:13 D:63 D:5 D:5 D:30 
Size method DLS DLS TEM DLS TEM TEM TEM 
Z-potential (mV) +2.3  - +29 -43 -53 -53 -56 
Dose (mg/kg) 28 45 0.56 0.95 85 11 85 
Dosing Bolus Bolus Bolus Bolus 1 h infusion 1 h infusion 1 h infusion 
Sampling times, post 
dosing (h) 
0.08, 0.17, 0.5, 1, 4, 
8, 24, 48, 72, 96, 120  
0.08, 0.17, 0.33, 
0.67, 1, 2, 4, 8, 24, 
72, 96, 120  
0.5, 1, 4, 16, 24, 72, 
168, 336, 672 
6, 24, 72, 168, 
720  
1, 20, 720  1, 20, 720, 2160 
Rat strain Sprague Dawley Sprague Dawley Sprague Dawley F344/DuCrlCrlj Sprague Dawley Sprague Dawley Sprague Dawley 
Bodyweight (g)* 253 253 160 a 244 425 440 441 
Number of animals 2-3 2-3 3 5 7-12 5 3-7 
Organs collected Bl, Li, Sp, Lu, Ki, He, 
Br, Lymp, BM, 
Carcass 
Bl, Li, Sp, Lu, Ki, He, 
Br, Lymp, BM, 
Carcass 
Bl, Li, Sp, Lu, Ki, He, 
Br, Bo, Mu 
Bl, Li, Sp, Lu, Ki, 
He, Br, Lymp 
Bl, Li, Sp, Br Ad, Bl, BM, Bo, Br, 
Fa, He, Ki, Li, Lu, 
Mu, Sk, Sp, Te, Ty 
Ad, Bl, BM, Bo, Br, 
He, In, Ki, Li, Lu, Mu, 
SF, Sk, Sp, Te, Ty 
Excretion U+F U+F U+F U+F  -  - U+F 
Analytical method C14 C14 ICP-MS ICP-SFMS ICP-MS ICP-MS ICP-MS 
Paper(s) I I+II II II III III III 
Reference Wenger 2011  Wenger 2011 Wang 2010  Shinohara2014 Yokel 2013 Yokel 2014 Yokel 2012 
a
 Bodyweight used in model  
Abbreviations: Ad – adrenal gland, Bl - blood, BM - bone marrow, Bo - bone, Br - Brain, C
14
 - carbon-14 radioactivity, CTAB - cetyltrimethylammonium bromide, D – Diameter, DLS – 
Dynamic Light Scattering, Fa – fat, F – Faeces, He - heart, ICP – Inductively Coupled Plasma, In - intestine, Ki - kidney, L – Length, Li - liver, Lu - lung, Lymp - lymph nodes, MS – Mass 
Spectroscopy, Mu - Muscle, PAA - polyacrylamide, PEG - polyethylene glycol, SF-spinal fluid, SFMS - Sector Field Mass Spectroscopy, Sk – Skin, Sp - spleen, Te – Testis, TEM – 
transmission electron microscopy, TiO2 - titanium dioxide, Ty – Thymus, U – Urine. 
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 Expansion of the PBPK model to nanoceria administered by various 4.1.3
routes 
Next, biokinetics for cerium dioxide nanoparticles (CeO2 or nanoceria) were characterized 
using the same model structure as in Paper II, but also modified to include inhalation, 
instillation and oral exposure (Paper III).  
Raw data were received from Yokel and colleagues on nanoceria infused intravenously into 
rats and additional biodistribution studies on intravenous, inhalation, instillation and oral 
exposure were collected from the literature. A literature review was performed using 
SciFinder, PubMed, Google Scholar and Web of Science and scrutinizing reference lists in 
papers. If data were presented as figures, data was extracted using WebPlotDigitizer version 
2.6. In total, we found 16 data sets from eight studies for intravenous exposure covering 
different sizes (3, 5, 15, 30, 40 and 55 nm), coatings (uncoated, citrate, citrate/EDTA coated), 
doses (between 6 and 750 mg/kg) and dosing methods (bolus and infusion) (Yokel et al., 
2009; Hardas et al., 2010; Dan et al., 2012; Yokel et al., 2012; Heckman et al., 2013; Yokel 
et al., 2013b; Yokel et al., 2014; Konduru et al., 2016). The number of inhalation and 
instillation studies was seven, including 16 data sets (He et al., 2010; Nalabotu et al., 2011; 
Geraets et al., 2012; Keller et al., 2014; Molina et al., 2014; Konduru et al., 2015b; Konduru 
et al., 2016; Li et al., 2016). Ingestion of nanoceria was described in four studies, covering 
nine data sets (Park et al., 2009; Kumari et al., 2014a; Kumari et al., 2014b; Molina et al., 
2014). For more information about collected studies, see Paper III.   
The richest data set/sets (most organs and at least three sampling times post-administration) 
among the biodistribution studies for intravenous administration were selected and used for 
optimization of PBPK models to experimental data on 5 and 30 nm nanoceria. To meet 
criteria on multiple organs and frequent sampling, two studies had to be used for optimization 
of PBPK model to 5 nm nanoceria (Yokel et al., 2013b; Yokel et al., 2014). For optimization 
of the model to 30 nm nanoceria, the richest data set, reported by Yokel and colleagues in 
2012, was employed (Yokel et al., 2012). The remaining data sets were utilized for validation 
of the model: four data sets for the 5 nm PBPK model and five for the 30 nm PBPK model. A 
summary of study characteristics for the three data sets used for optimization in Paper III is 
presented in Table 4. Data on 15 and 50 nm did not have sufficient information for model 
calibration, instead they were compared with predictions from the PBPK model calibrated to 
5 nm and 30 nm nanoceria.  
In addition to the work done in Paper II, the model’s predictability for independent data sets 
was evaluated (validation), as such data were available. The model was the same as in Paper 
II, but nanoparticle-dependent parameter in the model were re-optimized separately for 5 and 
30 nm nanoceria. We also tested two other models from other research groups, Lin and 
Bachler and their colleagues, but the outcomes from these models are not reported as they did 
not improve the results (Bachler et al., 2015b; Lin et al., 2016). 
The impact of exposure routes on biokinetics was compared with that of intravenous 
administration, by calculating and comparing the ratios between reported concentration in 
internal tissues/organs and the concentration in liver. To study differences in absorption 
efficiency, the mass ratios between liver and lung or liver and administered dose were 
calculated and compared for inhalation, instillation and oral data.  
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To simulate uptake into the circulatory system after oral and lung exposure, the PBPK model 
was modified by adding compartments for such exposure routes: one compartment for uptake 
from lung and one compartment for absorption from gastrointestinal tract. Absorption into 
systemic circulation was described by first-order kinetics. Clearance via the mucociliary 
escalator in lung and clearance to faeces in the gastrointestinal tract were expressed using 
first-order clearance rates. The clearance rate constants and the absorption rate constants in 
the modified model were estimated by fitting the constants, one by one, to each individual 
data set collected for inhalation, instillation and oral exposure. All other parameters of the 
model were kept the same as for the 5 nm PBPK model, but scaled to bodyweight in 
experiments. 
 Further refinement of the PBPK model to account for inhalation 4.1.4
exposure 
Inhalation of nanoparticles results in deposition of nanoparticles in the respiratory system, 
with potential uptake into the body. In Paper IV, we modified the PBPK model from Paper II 
to include this type of exposure route by including deposition in the respiratory system and 
transfer to the GI tract.  
Biodistribution data on nanoceria were produced and reported in Paper IV. A experimental 
system was developed to generate aged and pristine nanoceria and deliver the particles to the 
respiratory system. Aging involved exposure to ambient urban air conditions with UV light 
irradiation.  
Via a nose-only exposure chamber, Sprague Dawley rats were exposed to combustion-
generated nanoceria particles, aged and pristine, during 4 hours. Organs were harvested 15 
min, 24 h, and 7 days post-exposure and urine and faeces were collected for the first 24 
hours. 
In the PBPK model, the respiratory system is divided into three compartments; 1) upper 
respiratory tract, 2) tracheobronchial region, and 3) pulmonary region. Absorption from the 
respiratory system into lung tissue is assumed to take place in the pulmonary region 
following first-order kinetics. In the pulmonary region, alveolar macrophages can engulf 
deposited nanoparticles. The alveolar macrophages move the nanoparticles to the 
tracheobronchial region for clearance to mouth via the mucociliary escalator followed by 
swallowing into gastrointestinal tract. Alveolar macrophages were assumed to behave the 
same as other phagocytic cells in the model. Transport of alveolar macrophages to 
tracheobronchial region and clearance via the mucociliary escalator were described by first-
order kinetics.  
Deposition of nanoparticles in the upper respiratory tract may result in translocation of 
nanoparticles into the brain via olfactory and trigeminal nerves. Therefore, a first-order 
uptake rate into brain was included in the model. In addition, deposition of nanoparticles in 
the upper respiratory tract also results in swallowing into the gastrointestinal tract. In the 
gastrointestinal tract, uptake into the body can take place and was described by a first-order 
kinetics in the model.  
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 Computer software and numerical algorithms 4.1.5
All models in Papers I-IV were built in Berkeley Madonna
TM
 version 8.3.18 (Berkeley, CA) 
and acslX
TM
 Libero version 3.0.2.1 (Huntsville, AL). Berkeley Madonna was used for 
sensitivity analysis and acslX for optimization. 
To solve differential equations, different algorithms were used. Runge Kutta 4 was used for 
sensitivity analyses, because this algorithm has fixed step sizes. Fixed steps are required 
when predictions at exact time points are to be compared. On the other hand,nanoparticles 
covered in this thesis had biokinetic profiles that shifted between fast and slow processes, for 
such mixed processes Runge Kutta is too slow for optimization and here algorithms using 
variable step sizes are preferred, such as Gear and CVODE. Gear was used in Papers I and III 
and CVODE in Papers II and IV. 
Optimization was performed in asclX Libero using maximum log-likelihood estimation and 
Nedler Mead methods. Different algorithms and heteroscedasticities were tested, but in 
general Nedler Mead tended to give the best maximum log-likelihood values and varying 
heteroscedasticities had only minor impact on the results. To evaluate results from complex 
systems, such as PBPK modelling of nanoparticles, there are no general best methods to use 
and as a result the evaluation methods vary among research groups, see Table 1. In this 
thesis, the results were evaluated by determining the deviation from the line of unity between 
the log10 of observed and predicted values and calculating the corresponding R
2
. In Paper II, 
we also used the PBPK indices. In Paper IV, the predictability of the 5 nm PBPK model for 
nanoceria was evaluated using independent data sets. If the predicted values were within a 
factor 2 of the observed mean values, the model was considered to be adequately validated, a 
requirement proposed by the International Programme on Chemical Safety (IPCS, 2010). 
To identify model parameters that influence model outcomes the most, sensitivity analyses 
were carried out using normalized (relative) sensitivity coefficients. These sensitivity 
coefficients were calculated as the relative change in area under the mass-time curve divided 
by a change in parameter values. 
4.2 DISSOLUTION OF GOLD NANOPARTICLES 
An observation we made in Paper II was that the model did not capture the slow decrease in 
organs with low concentration of gold and titanium dioxide e.g. heart and kidney, which may 
be due to dissolution. If dissolution takes place, contrary to our PBPK model assumption, this 
will not only influence the biokinetics but also how PBPK models are designed and how 
toxicological findings should be interpreted. Nanoparticles are taken up by macrophages. 
Macrophages have the ability to release reactive oxygen species, which may dissolve 
apparently inert nanoparticles.  
To study this, we developed an in vitro method and evaluated dissolution of gold in cell 
medium, cell medium with macrophages or cell medium with macrophages triggered with 
LPS. This section provides an overview of this dissolution study. 
 Material – Gold nanoparticles 4.2.1
The dissolution study was carried out using citrated gold nanoparticles from Nanocomposix 
with diameters of 5 and 50 nm. Gold ions (from HAuCl4) were used to measure recovery of 
gold ions in the test system. 
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 Method 4.2.2
We investigated the dissolution of 5 nm and 50 nm gold nanoparticles at simulated healthy 
and diseased conditions, i.e., in macrophages and in LPS-triggered macrophages, as well as in 
cell medium only. Gold nanoparticles were incubated in cell medium (5 g/ml), with or 
without murine macrophages (RAW 264.7), for different time periods (0, 24 or 168 h).  
After exposure, cell medium and mechanically lysed cells were collected and centrifuged. In 
practice, the separation of small gold nanoparticles and dissolved gold ions/complexes 
constituted the crucial experimental challenge. The centrifugation efficiency was improved 
by the presence of mechanically lysed cells. To allow a direct comparison between the 
dissolution of gold nanoparticles in media (only) and in media with macrophages, cell lysate 
was also added to samples of media-incubated gold nanoparticles. By this simple, yet novel, 
procedure for handling critical separation of small gold nanoparticles and the dissolved 
fraction we ensured similar test conditions and avoided flaws in the comparison due to 
different centrifugation efficiencies. 
After centrifugation, the supernatant was collected, treated with aqua regia and analysed with 
inductively coupled plasma mass spectrometry (ICP-MS), to obtain quantitative results of 
gold dissolution after different time periods. The effect on gold nanoparticle dissolution and 
relationships between particle size, time of incubation and exposure conditions were 
evaluated using median linear regression modelling with correlation between all parameters. 
The dissolution method is summarized in Figure 3. 
 
 
Figure 3. Overview of the method for dissolution of gold nanoparticles in vitro. Step 1: 5 µg of 5 or 50 
nm gold particles or 0.25, 1 or 5 µg of Au
3+
 (from HAuCl4) were added to wells with cell medium, 
macrophages or macrophages triggered with LPS and incubated for 0, 24, or 168 h. Step 2: Cell 
medium was collected in e-tube. Water was added and the cells were mechanically lysed with a needle 
and a syringe. Lysed cells were transferred to e-tube with collected cell medium. Step 3: E-tubes were 
centrifuged for 30 minutes at 13,000 rpm. Step 4: The supernatant was collected and treated with 
aqua regia for at least 24 hours. Step 5: Aqua regia solution was diluted and internal standards were 
added, followed by ICP-MS analysis. 
1 2 3 4 5 
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5 RESULTS AND DISCUSSION 
This section summarizes the results and the discussions for Papers I-V. The first part relates 
to the development of nano PBPK models for nanoparticles considered inert, delivered to rats 
via intravenous administration, inhalation, instillation and ingestion (Papers I-IV). The 
second part describes a follow-up study from a finding in Paper II related to the dissolution of 
gold by macrophages (Paper V). 
5.1 PBPK MODELLING OF NANOPARTICLES 
 Development of a nano PBPK model for intravenous exposure  5.1.1
As a first step, a conceptual model for inert nanoparticles injected intravenously in rats was 
developed using polyethylene glycol-coated polyacrylamide (PAA-PEG) nanoparticles as the 
modelling substance (Paper I). The model accurately described the biokinetics of measured 
amounts of PAA-PEG in different organs (R
2
 on the log scale 0.97).  
According to the model, there was a fast initial clearance from blood because nanoparticles 
were rapidly distributed to organs, where phagocytic cells internalized them until these 
phagocytic cells became saturated. After four hours, phagocytic cells in most organs were 
saturated and free nanoparticles were distributed to the rest of the body. Phagocytic cells 
worked as a storage compartment for nanoparticles. In short, inclusion of a separate 
compartment for phagocytic cells was successful and a natural component of a PBPK model 
for nanoparticles.  
The sensitivity analysis indicated that the key determinants for the biokinetics of PAA-PEG 
nanoparticles are the uptake capacities of phagocytizing cells in organs, the partitioning 
between tissue and blood, and the permeability between capillary blood and tissues. 
5.1.1.1 Model structures and parameters 
Our model structure for intravenous exposure in Paper I, also used in Papers II-IV with 
modifications, has some similarities, but also differences, compared with published nano 
PBPK models, see Table 1. Differences are not only limited to which species and 
nanoparticles the models have been applied to, but also encompass how many compartments 
and parameters are included in each model, and how the models were evaluated. 
Consequently, results from one model cannot readily be compared with results from another, 
unless the models are applied to the same data sets; this has not been done yet, but would 
constitute an interesting next step.    
Since the publication of Paper I, the concept of phagocytic cells has been implemented in 
other models, but not necessarily in a similar way as in our model (Bachler et al., 2013; 
Bachler et al., 2015b; Lin et al., 2015a; Lin et al., 2016). The models by Lin and colleagues 
assume that the uptake of gold nanoparticles by phagocytic cells occurs directly from blood 
for larger gold nanoparticles (100 nm), whereas for smaller gold nanoparticles (10 nm) the 
uptake takes place in the tissue. To describe the uptake rate constant for phagocytic cells, they 
employed a time-dependent Hill equation, which introduced a more complex model structure 
with more parameters. In the first model from 2015, Lin and colleagues did not include 
saturation of phagocytic cells, but in a model reported by the same group in 2016 saturation 
was added and described as in Paper I (Lin et al., 2015a; Lin et al., 2016). Bachler and co-
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workers assumed that the uptake of titanium dioxide by phagocytic cells takes place directly 
from blood, and can be described by a one-compartment structure without saturation (Bachler 
et al., 2015b).  
Our model assumption is that phagocytic cells behave the same, but their densities in tissue 
vary (Papers I-IV). In reality, phagocytic cells are diverse and differ across organs, species 
and conditions of health (Gordon et al., 2005). The large variability obtained from the 
parameterization of the model coheres with the expected densities of phagocytic cells in 
tissues. We noticed the highest uptake capacity in organs such as spleen, liver and bone 
marrow, which is in line with other studies (Lang et al., 1992; Hyafil et al., 2007).  
Another simplification we made was to assume a single mechanism for phagocytosis, when 
in fact multiple endocytotic pathways exist (Sahay et al., 2010; Canton et al., 2012). 
Endocytosis has also been shown in vitro to be highly dependent on the properties of the 
nanoparticles as well as agglomeration and the corona formation (Chithrani et al., 2006; Jiang 
et al., 2008; Luciani et al., 2009; Albanese et al., 2011; Lesniak et al., 2012). In our model, 
the phagocytic process is saturable and involves an uptake rate constant (one for the spleen 
and another for all other organs), a single release rate constant and a single maximal uptake 
capacity constant. In models developed to describe the kinetics for uptake of nanoparticles in 
vitro, more process steps are included than in our model, i.e., adherence to the cell membrane 
prior to engulfment and reprocessing of receptors required for endocytosis (Wilhelm et al., 
2002; Ohta et al., 2012). We considered incorporation of in vitro models for phagocytosis 
into our own, but since extensive experimental data is not available this could lead to over-
parameterization.  
The modelling suggested that PAA-PEG had a preference for blood and a partition 
coefficient between tissue and blood was introduced to describe this behaviour. The partition 
coefficient may reflect the dynamic formation of corona formed around the nanoparticles, but 
the mechanism behind this is not fully understood. Corona formation is a dynamic process 
that is highly influenced by the properties of the nanoparticles, such as size, surface charge, 
shape and coatings and the biological environment (Cedervall et al., 2007; Nel et al., 2009).  
Another difference with our model compared with other models is the inclusion of a 
parameter to account for residual blood in organs after harvesting. The experimental data on 
PAA-PEG indicated that levels in blood and brain were correlated, with parallel curves. In 
addition, when analysed, the brain contained residual blood. Therefore, we assumed that the 
blood-brain barrier is impermeable and that nanoparticles are actually present in residual 
blood. If residual blood is not taken into consideration, the conclusion may be that the 
nanoparticles are taken up, even when they are not (Frigell et al., 2014). Unfortunately, 
biodistribution studies rarely report how harvesting was carried out and the measured level of 
nanoparticles in organs as brain and heart is often low. This makes measurement, 
visualization and model optimization challenging and sometimes uncertain. 
 Expansion of the PBPK model to other nanoparticles given 5.1.2
intravenously 
To investigate how generalizable the model developed in Paper I was for other nanoparticles 
considered inert, the model was applied to three additional types of nanoparticles (Paper II). 
In total, data sets from four different types of nanoparticles were used: PEGylated 
polyacrylamide (PAA-PEG), polyacrylamide (PAA), gold and titanium dioxide (TiO2).  
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The data sets for these four particle types differed substantially both in nanoparticle 
properties and study design. Despite this, the model adequately described the biokinetics for 
all four, excepting the slow decrease with time observed for the amounts of gold and titanium 
dioxide in organs with low content, such as heart (R
2
 on the log scale ranging from 0.88 to 
0.96).  
The differences in properties among the four types of nanoparticles were reflected by 
differences in values of nanoparticle-dependent model parameters. PAA and PAA-PEG had 
more similar values than gold and titanium dioxide. PAA was more readily cleared from 
blood than PAA-PEG, as a result of a 3-fold higher uptake rate constant to phagocytic cells. 
On the other hand, clearance from blood was much faster for gold and titanium dioxide than 
for PAA and PAA-PEG. According to the model, this was partly a result of faster uptake into 
phagocytic cells in spleen (> 9-fold higher ksab0) and easier access to liver, spleen, bone 
marrow and brain (> 100-fold higher Xfast) for gold and titanium dioxide, respectively, 
compared with PAA and PAA-PEG. The time courses for gold and titanium dioxide look 
similar but in fact also differ, mainly because the uptake rate by phagocytic cells was much 
higher for titanium dioxide than for gold (> 6-fold difference), and titanium dioxide had a 
higher preference for tissue than gold (P was 0.97 for titanium dioxide and 0.13 for gold), but 
lower permeability into tissues (5- to 9-fold). 
Another interesting result was the dose dependence. Higher doses saturate the phagocytic 
cells, which profoundly modifies biokinetics. The doses used for PAA and PAA-PEG were 
more than 30 times higher than for gold and titanium dioxide. As a result of this, more 
phagocytic cells became saturated for PAA and PAA-PEG than for gold and titanium 
dioxide.  
We tested different grouping of organs connected to the three permeability coefficients in the 
model. The results demonstrated that the best fitting was achieved when the high 
permeability coefficient (Xfast) was assigned to liver, spleen and bone marrow. This grouping 
also reflected the anatomical structure of endothelium most accurately (Sarin, 2010; 
Setyawati et al., 2015). In addition, and in contrast to Paper I, a low permeability over the 
blood-brain barrier had to be implemented to describe the levels of gold and titanium dioxide 
in brain. 
The results from the sensitivity analysis demonstrated that even if the model structure is the 
same for all four types of nanoparticles, the different values on model parameters resulted in 
totally different sensitivity coefficients. In this study, this is partly a consequence of the 
saturation level of phagocytic cells. Our results suggest that sensitivity analysis cannot be 
done only once; it should preferably be updated when model parameters are changed.  
5.1.2.1 Data for modelling 
PBPK modelling requires data. To collect data for Paper II, we carried out an extensive 
literature review. However, as we and other researchers have experienced, access to 
published data useful for modelling is sparse. Partly, this is a result of study objectives 
differing from ours. In all biodistribution studies reviewed, the majority of reported aims 
focused on comparing biodistribution profiles for different nanoparticles, identifying target 
organs, or linking toxicity to a target dose.  
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For our purposes (Paper II), we reviewed data reported for nanoparticles with a variety of 
properties and applications, including gold, silver, titanium dioxide, silica and polymers, 
administered to rats via a single intravenous injection. These data exhibited serious 
limitations for modelling, including: (1) incomplete characterization of the nanoparticles and 
dose, (2) short follow-up after dosing, (3) analysis of only a few samples per tissue and only a 
few tissues per organ, (4) failure to account for the mass balance, and (5) lack of confirmation 
of nanoparticle integrity in the tissues. Such limitations make modelling of the time course, 
half-life and bioaccumulation difficult. Overall, our review revealed the complexity involved 
in drawing general conclusions about nanoparticle biodistribution, with no individual factor 
such as size, coating, shape, charge, chemical composition or agglomerations providing a 
complete explanation. In choosing among all reviewed studies (> 200 data sets), we decided 
to focus on inert nanoparticles and three additional data sets were found.  
In short, the quality of the data sets used has a large impact on the modelling result and 
therefore we recommended in Paper II that new biodistribution studies should preferably 
involve: “1) extensive characterization of NPs (size, size distribution, integrity, etc.), 2) 
monitoring of several organs at several time points, 3) frequent sampling immediately after 
dosing, 4) long follow-ups, 5) determination of the mass balance (total recovery), and 6) a 
detailed description of the analytical procedures employed (specificity, limits of detection, 
background levels, etc.)”.  
5.1.2.2 Model structure and parameters 
The description of uptake capacity of phagocytic cells was modified by separating the 
phagocytic uptake capacity constant in Paper I into two constants. The first constant reflected 
the uptake capacity of an individual phagocytic cell (nanoparticle-dependent) and the second 
constant described the density of phagocytic cells in the tissue (nanoparticle-independent). 
This separation makes it possible to compare uptake capacity of phagocytic cells predicted by 
the model with experimental data from in vitro studies.  
The predicted uptake capacity of an individual phagocytic cell for the particles of PAA-PEG, 
PAA, gold and TiO2 are in the range of those previously reported in vitro (Alkilany et al., 
2010; Ferrari et al., 2014). The model suggested that the maximum uptake capacity is in the 
range of 0.5-5 pg per phagocytic cell, which corresponds to 2,000-300,000 NPs per 
phagocytic cell. Alkilany measured an uptake of 45-150,000 gold nanoparticles per cell and 
Ferrari and co-workers reported 45-10,000,000 polymeric nanoparticles per cell, depending 
on cell line, composition, size, charge and dose of nanoparticles. Hence, the in vitro values 
varied substantially, by several orders of magnitude. These large differences in uptake rate 
may reflect differences in nanoparticle properties, but also the method used to measure and 
model the uptake. In fact, the cellular dose in an in vitro system depends on how the 
nanoparticles interact, diffuse, settle and agglomerate in the cell medium (Teeguarden et al., 
2007; Hinderliter et al., 2010; Cohen et al., 2013). 
The finding that the prediction of brain levels of PAA on the basis of residual blood is not as 
accurate as for PAA-PEG may reflect a slight difference in the way the organ was harvested, 
leaving a smaller amount of blood for PAA than for PAA-PEG. However, residual blood 
cannot explain the biokinetics of gold and TiO2 nanoparticles with respect to the brain, since 
the level in blood approaches background levels. In these cases, brain levels must represent 
something else, probably uptake, in line with what has been observed by other researchers 
(Sonavane et al., 2008; Kolhar et al., 2013; Yokel et al., 2013a; Frigell et al., 2014; Geraets 
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et al., 2014). These problems with residual blood illustrate the importance of an accurate 
description of how organs are harvested, which, unfortunately, is often lacking and 
contributes uncertainty in the modelling results.  
 Expansion of the PBPK model to nanoceria administered by various 5.1.3
routes  
As a next step, we wanted to model the systemic distribution of cerium dioxide nanoparticles 
(nanoceria). We first collected experimental biodistribution data on nanoceria in rats (various 
exposure routes, sizes, coatings and tissues sampled) from the literature. Next, the PBPK 
model was calibrated and validated against data for 30 nm citrate-coated nanoceria, followed 
by recalibration and revalidation for 5 nm nanoceria. Finally, the model was modified and 
tested against inhalation, instillation and oral nanoceria data.  
The model adequately described (R
2
 = 0.91) and predicted the biokinetics of 5 nm nanoceria 
infused into rats, but failed to do so for other sizes, although some predictions were 
reasonable, e.g., for liver and spleen. The 5 nm model could predict the values of new data 
within 2-fold for 17 out of 24 values for the 5 nm nanoceria, but the model under-predicted 
the concentration in blood at every time point for 3 nm nanoceria with a coating different 
from that of the 5 nm data sets. On the other hand, this result is in agreement with the opinion 
of Heckman and co-workers (Heckman et al., 2013).    
The experimental studies collected for 5 nm nanoceria were more similar than the studies for 
30 nm nanoceria, both as regards the properties of the nanoparticles used and the study 
designs. This probably explains our problem in describing the biokinetics for the 30 nm 
nanoceria. The doses administered for 30 nm nanoceria ranged between 6 and 750 mg/kg, 
whereas the doses ranged between 10 and 85 mg/kg for 5 nm nanoceria. The experimental 
data for the 30 nm nanoceria suggested dose-dependent biokinetics. When the concentration 
was increased from 6 to 87 mg/kg, the concentration-time profile in blood, kidney and lung 
changed over time and 3 months after the administration of the highest dose the concentration 
increased. This behaviour cannot be described by the existing model and the mechanism 
behind it is not fully understood. However, a higher dose may trigger an inflammatory 
response resulting in recruitment of phagocytic cells. Phagocytic cells may dissolve the 
nanoceria and thereby change the biokinetics. Dissolution of nanoceria has been observed 
and cerium ions have been demonstrated to have a different biokinetic profile than nanoceria 
(Graham et al., 2014; Molina et al., 2014). On the other hand, the biodistribution profile for 
ions cannot explain the change in biokinetics for 30 nm nanoceria, which suggests a more 
complex mechanism.  
In agreement with the conclusions of previous researchers, the compilation of data from 
biodistribution studies on inhalation, instillation and oral exposure points to a low systemic 
uptake. Less than 1 mass % (median) of the lung burden was transported to the liver and less 
than 0.01 mass % (median) of the administered oral dose was distributed to the liver, Figure 
4.  
Plotting the concentration ratios between organs (blood:liver, spleen:liver, brain:liver) over 
time suggested substantial dependence on the administration route (iv, inhalation, instillation, 
and ingestion). The ratios differed by several orders of magnitude and the shape of ratio-time 
curves varied. In comparison, the ratio-time curve following intravenous administration 
differed marginally between studies, in spite of the different sizes, coatings and doses, 
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whereas studies using other exposure routes showed ratio differences several orders of 
magnitude greater. 
 
 
 
Figure 4.Comparison of experimental data on nanoceria by plotting the ratios between amount in 
liver and amount in lung or dose after inhalation, instillation and oral exposure in rats (Park et al., 
2009; He et al., 2010; Nalabotu et al., 2011; Geraets et al., 2014; Keller et al., 2014; Kumari et al., 
2014a; Kumari et al., 2014b; Molina et al., 2014; Konduru et al., 2015a; Li et al., 2016).The circles 
represent individual data and the solid line is the median value. 
Re-optimization of the model to inhalation, instillation and oral exposure was not successful, 
mainly because the absorption via these routes was low, with low and variable nanoceria 
levels in tissues. Despite this, the time course pattern appeared to differ from the intravenous 
data and proved hard to reproduce.  
Overall, our modelling results suggest that the biokinetics of nanoceria depend not only on 
the nanoparticle properties (size, coating), but also on the exposure conditions (dose, 
exposure route). 
5.1.3.1 Model structure and parameters  
The model structure was the same as in Paper II, but modified to include systemic uptake 
from the lung and gastrointestinal tract. The implemented modifications to the model were 
not successful and the modified model could not describe the systemic distribution of 
experimental data from inhalation, instillation and oral exposure. However, a complicating 
factor during modelling was access to rich data sets. Moreover, experimental data reported 
low uptake of nanoceria via these types of exposure routes, making the levels in internal 
organs low with large variability and often no significant differences between the organs.  
Despite these limitations, the model structure may be too simplistic to describe the uptake 
process in the lung and gastrointestinal tract. In the lung, deposited nanoparticles can be 
transported via mucociliary clearance to the larynx followed by swallowing into the 
gastrointestinal tract (Oberdörster, 1988; Snipes, 1989). Mucociliary clearance is described in 
the model, but not translocation into the stomach and potential later systemic uptake from this 
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region. On the other hand, the uptake from the gastrointestinal tract appeared to be much 
lower than from the lung and the clearance rate from the lung is much lower than in the 
gastrointestinal tract, making exposure from the lung almost continuous. 
In the lung, particles can also translocate into the lymphatic system, which the model does not 
describe. On the other hand, data in local lymph nodes were only reported in one of seven 
studies. In this model the lung is described with one compartment, which might be too 
simplistic. In Paper IV, we introduce a more complex structure for the lung. 
The gastrointestinal tract is, like the lung, only represented as a single compartment. Here too, 
the systemic uptake may be more complex than a first-order absorption rate constant into the 
systemic circulation. Once again the lymphatic system is not included in the model, but none 
of the collected studies reported such data.  
 Further refinement of the PBPK model to account for inhalation 5.1.4
exposure 
The PBPK model was refined to account for the complexity of inhalation exposure using data 
generated within the study, from a short-term inhalation exposure to aged and pristine 
nanoceria in rats. The model includes mucociliary clearance, olfactory uptake, phagocytosis, 
and entry into the systemic circulation by alveolar wall penetration. The PBPK model 
described the biodistribution well and again suggested phagocytosis as a key process for 
biokinetics. 
No significant differences either in biodistribution or properties between aged and unaged 
nanoceria were found. The majority of inhaled nanoparticles were recovered in the lung or in 
faeces and the levels decreased over time. Despite differences in the inhaled dose, the amount 
of nanoceria recovered in extrapulmonary organs was similar, within 65 % of each other. We 
think this reflects the amount of smaller particles with sizes less than 70 nm. According to the 
scanning mobility particle size data, this fraction of particles varied less than 31%. The 
majority of nanoceria was recovered in faeces, followed by the lung. In total, less than 4 % 
was detected in extrapulmonary organs. 
The model, expanded to inhalation exposure, described the measured data in the four 
experiments well (R
2
 on the log scale ranging from 0.68 to 0.95). However, the increase in 
levels in extrapulmonary organs could not be captured. 
The model predictions were sensitive to changes in model parameters, such as the fraction of 
inhaled nanoparticles deposited in the upper airway and in the pulmonary region, the faeces 
clearance rate from the GI tract, the uptake rate from the GI tract, the partition between blood 
and tissue and the permeability coefficient connected to lung, kidney, heart and carcass. 
5.1.4.1 Model structure and parameters 
The model structure for the systemic distribution was the same as in Paper II, but expanded to 
include the respiratory system. To describe the respiratory system, a similar structure as that 
used by Sweeney and colleagues was added to the model (Sweeney et al., 2015; Carlander et 
al., 2016). The respiratory system was represented by three compartments: 1) the upper 
airway, 2) the tracheobronchial region, and 3) the pulmonary region and the gastrointestinal 
tract with one compartment. 
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Following inhalation, nanoceria are deposited in the three regions. Deposited nanoparticles 
can be cleared (Oberdörster, 1988). In the upper airway, the model assumes that swallowing 
into the gastrointestinal tract clears the nanoceria. In the tracheobronchial region, the main 
clearance mechanism is the mucociliary escalator to the larynx and further transport into the 
gastrointestinal tract (Oberdörster, 1988; Snipes, 1989). In the pulmonary region, the particles 
can be engulfed by alveolar macrophages and transferred to the bronchial region or 
translocate into the interstitium.   
Initially, we tried to use the deposition fraction calculated from the Multiple-Path Particle 
Dosimetry Model (MPPD v 2.11), but this was not successful. The strategy was changed and 
the deposition was fitted to observed data instead, assuming the same deposition fraction for 
all four runs. Interestingly, the fitted deposition fractions in the tracheobronchial and 
pulmonary regions calculated using the expanded PBPK model were lower than those 
calculated using the Multiple-Path Particle Dosimetry Model (MPPD v 2.11), while the 
deposition fraction in the upper airway region was higher. This could be explained by 
agglomeration. The original size of the nanoceria is 2-3 nm, but on their way to the animals 
the nanoceria agglomerate, as recorded by the scanning mobility particle sizer (SMPS) 
measurements. It is likely that the agglomeration continues after the SMPS measurements 
until the nanoceria get inside the animals, as the equipment is not in direct contact with the 
animals. Moreover, in the respiratory system the air conditions change and become more 
humid, which may increase agglomeration. Increased agglomeration leads to a higher 
deposition fraction in the upper airways, with fewer particles reaching the lower respiratory 
regions.  
More than half of the recovered amount of nanoceria was found in faeces. This was much 
higher than the fraction reported by He and colleagues, who had approximately 20 % dose 
recovery in faeces (He et al., 2010). On the other hand, He and co-workers used instillation 
with a bolus dose, which excludes deposition outside the lung, limiting transport to the 
gastrointestinal tract only to mucociliary clearance. In this study, the nanoceria were 
delivered in a nose-only inhalation chamber and deposition in the upper airway, as well on 
the whiskers and snout, will take place and contribute to the ingestion of nanoceria. In whole 
body exposure chambers, deposition on the fur followed by licking also adds to the ingestion 
of nanoceria. Unfortunately, many studies do not report the amount in faeces, urine and total 
recovery, which limits the ability to compare results and develop nano PBPK models. For 
nanoceria, the model predicted that the uptake to extrapulmonary organs mainly came from 
translocation from the lung. This is in agreement with other researchers, who have reported 
that uptake from the gastrointestinal tract is lower than from the lung (Yokel et al., 2012; 
Molina et al., 2014).  
Several research groups have showed that, in the lung, nanoparticles translocate to the 
lymphatic system, that this translocation depends on nanoparticle properties, such as size, and 
that it increases with increased lung burden (Tran et al., 2000; Choi et al., 2010; Keller et al., 
2014). Our model does not include the lymphatic system, mainly because we did not have 
access to such data. Adding a compartment for the lymphatic system without the ability to 
calibrate this to experimental data would increase uncertainty and enhance the complexity of 
the model. We therefore decided to exclude the lymphatic system until data was available. In 
our study, the lymph nodes around the lung were not removed before the lung was analysed. 
Even if the concentration in the local lymph nodes would be high, the amount in local lymph 
nodes would contribute negligibly to the overall amount in the lung, because of their small 
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size and limited translocation. In our study, the inhalation concentration was more than ten 
times lower compared with studies showing increased translocation to the lymph nodes 
(Keller et al., 2014). In other studies, we have noticed that it is often unclear whether lymph 
nodes have been removed or not before analysis of the lung.   
Another limitation with this study is the large variability in some of the experimental data, 
which may result from for example the individual behaviours of rats, differences in delivered 
concentration and methodology. This variability combined with low concentration in 
extrapulmonary tissues contributed to uncertainties in the optimization of the model.  
5.2 DISSOLUTION OF GOLD NANOPARTICLES 
Most published PBPK models for nanoparticles, including our own, do not include 
dissolution processes of nanoparticles. One explanation might be that the common opinion is 
that nanoparticles used for modelling, such as gold, titanium dioxide, nanoceria and quantum 
dots, do not dissolve during the relatively short time period described by models. However, if 
models are going to be used for humans, long-term exposure scenarios are required and then 
dissolution of nanoparticles might be a relevant, even critical, process (Misra et al., 2012; 
Utembe et al., 2015; Feliu et al., 2016a). Another aspect is that the biokinetics and the 
toxicities of dissolved entities may differ from those of the particles (Molina et al., 2014; 
Sabella et al., 2014). Consequently, if dissolution takes place, this process should be 
implemented into PBPK models. Implementing dissolution processes into a PBPK model 
might seem straightforward, but in fact it is not, because the models get more complex and 
require experimental data on the biokinetics of nanoparticles and dissolution species that are 
not yet available. In addition, the kinetics of dissolution of nanoparticles considered inert, 
such as gold in a biological environment, have not yet been described in the literature.  
In Paper V, we wanted to challenge a common opinion that gold is inert. This was due to 
results from our modelling efforts in Paper II suggesting that gold might dissolve over time. 
Combined with information from the literature, this triggered us to create a hypothesis: Gold 
can be dissolved by macrophages.  
To test this hypothesis, an in vitro method was developed to compare the dissolution of 
AuNPs in i) cell medium, ii) macrophages, and iii) LPS-triggered macrophages (simulating 
inflammatory conditions), using Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
measurements of gold in the media.  
We exposed the in vitro system to 5 µg/ml of 5 nm and 50 nm gold nanoparticles for 0, 24 
and 168 h (1 week). A clear, time-dependent dissolution of the 5 nm AuNPs was seen already 
in the cell medium, corresponding to 3 % and 0.6 % of the added amount of 5 nm and 50 nm 
AuNPs, respectively, after 1 w (168 h) of incubation. The dissolution of 5 nm AuNPs was 
further increased to 4 % in the presence of macrophages and reached 14 % after LPS-
triggering. In contrast, no such increases were observed for 50 nm AuNPs, except after 1 w in 
the presence of LPS.  
The size-dependent dissolution of gold nanoparticles in cell medium (without cells) can be 
explained by differences in surface area and agglomeration. We observed lower differences 
(three- to six-fold) in dissolution than would be expected from surface area differences (ten-
fold), but on the other hand, 5 nm nanoceria appear to agglomerate more than 50 nm 
nanoceria, which would reduce the differences. In contrast, dissolution in the presence of 
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triggered macrophages cannot be explained by increased agglomeration or uptake of 5 nm 
nanoceria. In agreement with results reported by other researchers, we found higher cell doses 
(NPs taken up or attached to cells) for the 50 nm AuNPs (approx. 80 % of added amount) 
than for the 5 nm (approx. 60 %) after 24 h (Chithrani et al., 2006). After 1 week, the 
dissolution was 5-fold higher when 5 nm nanoceria were exposed to triggered macrophages 
than when exposed to the cell medium only, whereas for 50 nm nanoceria, the dissolution 
was only slightly increased. A more likely explanation is that the inherent properties of the 
small AuNPs, such as higher surface energy, catalytic activity and defects of the surface, are 
the main reasons for the observed difference in gold dissolution in the presence of 
macrophages (Clarke et al., 2001; Zhou et al., 2010). 
We were interested in the total release of dissolution products from gold, i.e., both inside, on, 
and outside the cell, and therefore both the cell medium and the cells were collected at the 
end of incubation. The cells were mechanically sheared to provide a cell lysate before being 
mixed with the cell medium. In practice, the separation of small gold nanoparticles and 
dissolved gold ions/complexes turned out to be an experimental challenge, especially for our 
gold nanoparticles incubated in cell medium (only). When we added unexposed cell lysates to 
the gold nanoparticles incubated in cell medium (only), the centrifugation efficiency was 
improved and the variations in results reduced. This novel but simple process ensured similar 
test conditions for all samples.   
When macrophages are triggered with LPS, a condition of oxidative stress is induced and the 
production of reactive oxygen species is elevated (Forman et al., 2002; Gantner et al., 2003). 
Hydroxyl radicals are reactive oxygen species with high redox potential, even higher than 
gold, and consequently dissolution of gold through an electrochemical process is possible 
(Mohr, 2009). We therefore expected that triggered macrophages would increase dissolution, 
which was confirmed in this study.   
The high redox potential of gold suggests that gold is not easily dissolved and released gold 
ions will easily be reduced back to elementary gold. To test if the method could detect gold 
ions in the cell medium, we performed a recovery test by incubating cell medium with gold 
ions followed by lysate-assisted centrifugation. We added gold ions (0.25 µg in 1 ml) to the 
cell medium, and recovered approximately 70 % of the added gold amount. As expected, a 
lower percentage was detected when higher concentrations were used (1 and 5 µg in 1 ml). 
This is interesting because it is far higher than the results from classical thermodynamic 
equilibrium modelling (Joint Expert Speciation System, version 8.3). According to the 
modelling, only 0.4 % (for the highest gold concentration of 5 µg/mL) and 8 % (for the 
lowest gold concentration of 0.25 µg/mL) would be in solution as gold hydroxide (AuOH). 
However, thermodynamic equilibrium modelling only includes certain components in cell 
medium as input for calculations of properties in test medium, such as pH and ion strength, 
but possible reactions between gold and biological substances in the medium is not accounted 
for. Indeed, our results suggest that such reactions are critical and gold has been shown to 
interact with thiols, cyanides and amino acids (components of cell medium and lysed cells), 
generating ligands with dissolved gold ions (Brown et al., 1982; Larsen et al., 2007; Mohr, 
2009; Paulsson et al., 2009). The next step is to identify where the dissolution takes place, 
characterize the constitution of the gold ions/complexes formed and take a closer look at the 
dynamics and processes inside the cells. Another improvement would be to update classical 
thermodynamic equilibrium models with information about reactions between gold and 
biological substances.
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6 CONCLUSIONS 
In this thesis, a PBPK model for nanoparticles considered inert has been developed. The 
model adequately describes the biokinetics of different types of inert nanoparticles given 
intravenously into rats, despite large differences in properties and exposure conditions (PAA-
PEG, PAA, gold, titanium dioxide and nanoceria). In addition, after modification to account 
for the complexity of inhalation exposure of nanoparticles, the model well captured the 
biokinetics of nanoceria inhaled by rats. Uptake of nanoparticles by phagocytic cells was 
identified as a critical process. This process is saturable and has great impact on the 
biokinetics of nanoparticles. Our model was the first to include saturable phagocytic cells and 
has been copied by other research groups and we argue that phagocytic cells should be a 
natural compartment in nano PBPK models. However, nano PBPK models are still in their 
infancy and require further development to better reflect processes such as agglomeration, 
corona formation and dissolution.   
Validated PBPK models can describe and predict how substances are taken up, distributed, 
degraded and excreted from the body, even when the relationship between external and target 
dose is non-linear. Our results indicate that this is the case for biokinetics of nanoparticles, 
meaning that a validated nano PBPK model would be of great value to risk assessors, who 
often need to extrapolate exposure risks for humans on the basis of animal data. Our model 
represents a first step in that direction. In the future, it needs to be validated for different 
exposure routes and species. This was not yet possible, because experimental data are not 
available. In a next step, more experimental data are needed to predict the behaviour of new 
types of nanoparticles in order to link their properties to model parameters. 
PBPK models are not limited to use only in risk assessment. This thesis clearly demonstrates 
that modelling also contributes to evaluating the quality of biodistribution studies, identifying 
knowledge gaps, and to generation and testing of hypotheses.  
The review of biodistribution studies points to the need for improved control and reporting of 
study results. Such improvements should involve more detailed reporting of nanoparticle 
characteristics and methodology.  
Even though a lot has been published on how the biokinetics of nanoparticles are influenced 
by their properties (such as size, shape, surface chemistry, and agglomeration) and their 
interaction with the bio-environment (corona formation, phagocytosis, dissolution), these 
factors are not well characterized in quantitative terms and thus not readily implemented in 
PBPK models for nanoparticles. This illustrates the need for quantification of such factors.  
The modelling efforts also demonstrate that results may lead to new hypotheses, as in Paper 
II, where we generated a hypothesis that gold is dissolved by macrophages. In Paper V, we 
tested the hypothesis and demonstrated that macrophages in vitro can dissolve gold 
nanoparticles.   
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7 FUTURE PERSPECTIVES 
 
The existing nano PBPK models are of limited use for risk assessment, since they cannot 
readily be applied to new types of nanoparticles, species or conditions of exposure without 
access to experimental data. Improvement of available models requires appropriately 
designed investigations of biodistribution. Today, for example, most published PBPK models 
are limited to short-term exposure and single doses. To make models useful for humans, 
long-term exposure and repeated doses need to be implemented. Extrapolating short-term 
results to long-term and repeated exposure is not recommended because the rate-limiting 
factors driving the biokinetics may change over time. So far data for such exposure 
conditions are sparse; thus, this field needs further attention.  
 
Another important improvement of study designs would be to combine in silico, in vitro and 
in vivo approaches, which would help to answer some of the currently most urgent questions 
in the field: Can we choose model parameters on the basis of the physicochemical properties 
of the nanoparticles? What key factors, including species differences, dictate the biokinetic 
behaviours of these particles? How do we implement the dynamic behaviour of corona 
formation, agglomeration and dissolution into our models? 
 
In addition to extrapolating and combining current findings/knowledge to predict the impact 
of nanomaterials on different organs and different species, in silico procedures, such as 
principle component analysis (PCA), quantitative structural activity relationship 
(QSAR/QNAR) and PBPK, can help in the design of robust in vivo studies by providing 
information about, e.g., structural patterns in data, relationships between parameters and toxic 
endpoints, and appropriate dosing and sampling frequencies.  
 
Continuous improvements of in vitro methods make them more and more similar to the in 
vivo situation. Today, we know much about the mechanisms by which nanoparticles are taken 
up by cells, but less about uptake kinetics and even less about nanoparticle release.  
Most important for good PBPK model development is access to experimental data. However, 
data on physiological parameters are unfortunately not as easily found as we thought. 
Databases developed for collection of such data are often not public and those that are public 
are often not updated. Requiring the reporting of such data into databases, as carried out for 
reporting of genomes, would improve the quality of models, as well as contributing to the 
3Rs (reduction, refinement and replacement) of animal testing. 
My belief is that focus and cross-scientific collaboration will generate useful nano PBPK 
models in the future. But, as usual, hard work is required. 
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